Recombinant cardiomyocytes and cardiomyocyte cell lines expressing herg

ABSTRACT

The present disclosure relates generally to recombinant cardiomyocytes and cardiomyocyte cell lines overexpressing hERG and uses thereof.

This application claims the benefit of and priority to U.S. ProvisionalApplication No. 62/395,371, filed Sep. 15, 2016, the entire content ofwhich is incorporated by reference herein in its entirety.

1. TECHNICAL FIELD

The present disclosure relates generally to recombinant cardiomyocytesand cardiomyocyte cell lines expressing hERG and uses thereof.

2. BACKGROUND

Cardiotoxicity is a leading cause of attrition in clinical studies andpost-marketing withdrawal. The human Ether-a-go-go Related Gene 1(hERG1) K⁺ ion channel is implicated in cardiotoxicity. Therefore,screening of candidate drugs for activity against cardiac ion channels,including hERG1, is recommended.

The hERG1 ion channel (also referred to as KCNH2 or Kv11.1) is a keyelement for the rapid component of the delayed rectified potassiumcurrents (I_(Kr)) in cardiac myocytes, required for the normalrepolarization phase of the cardiac action potential (Curran et al.(1995) Cell 80: 795-803; Tseng (2001) J. Mol. Cell. Cardiol. 33: 835-49;Vandenberg et al. (2001) Trends. Pharm. Sci. 22: 240-246). Loss offunction mutations in hERG1 cause increased duration of ventricularrepolarization, which leads to prolongation of the time interval betweenQ and T waves of the body surface electrocardiogram (long QTsyndrome-LQTS) (Splawski et al. (2000) Circulation 102: 1178-1185;Witchel et al. (2000) Clin. Exp. Pharmacol. Physiol. 27: 753-766). LQTSleads to serious cardiovascular disorders, such as tachyarrhythmia andsudden cardiac death.

In vitro screening of candidate drugs for activity against the hERGcardiac ion channel have generally involved the use of non-cardiac celllines (e.g., human embryonic kidney (HEK 293) cells and Chinese hamsterovary (CHO) cells; see, e.g., Haraguchi et al. (2015) BMC PharmacolToxicol. 16: 39) for the prediction of drug-induced ECG abnormalities.There remains a need for suitable cell lines derived from cardiac cells,for improved in vitro screening of compounds for drug discovery and/ordrug development.

3. SUMMARY

The present disclosure provides novel recombinant cardiomyocytes andcardiomyocyte cell lines, and methods for their use, including forscreening compounds for cardiotoxicity.

Provided herein are recombinant cardiomyocytes and cell lines, includingstable cell lines, that comprise a transfected or transduced nucleicacid sequence encoding hERG. In some embodiments, hERG comprises anamino acid sequence (see, e.g, amino acids 1-1159) as set forth in SEQID NO: 1.

In some embodiments, the recombinant cardiomyocytes are designatedhMYO-hERG. In some embodiments, the recombinant cardiomyocytes aretransduced adult human ventricular cardiomyocytes. Exemplary cellsinclude those deposited as ATCC Designation No. PTA-123324, or progeny,derivatives or descendants from the cells, including from culturingPTA-123324 cells to obtain progeny, derivative or descendant cells.

Provided herein are methods of preparing cell lines, wherein the celllines comprise recombinant cardiomyocytes expressing hERG and stablecell lines comprising such cardiomyocytes. In some embodiments, methodsas provided herein comprise transfecting or transducing immortalizedcardiomyocytes, including for example, immortalized adult humanventricular cardiomyocytes, with a nucleic acid sequence encoding hERG.In some embodiments, the nucleic acid sequence is transferred on avector by transfecting or transducing the vector. In some embodiments,the vector is a retroviral vector, such as a lentiviral vector. In someembodiments, when the vector is a lentiviral vector, the method furthercomprises the step of generating pseudo-lentiviral particles.

Provided herein are methods for determining cardiotoxicity (e.g.,hERG-related or non-hERG-related) of compounds using recombinantcardiomyocytes or cardiomyocyte cell lines as provided herein.

Provided herein are methods of screening compounds for cardiotoxicity,the methods comprising using recombinant cardiomyocytes or cardiomyocytecell lines as provided herein, including in methods for determining theactivity of compounds to inhibit hERG.

In some embodiments, provided herein are methods for determining theactivity of a compound to inhibit hERG (e.g., by blocking or obstructinga hERG channel), wherein the methods comprise using recombinantcardiomyocytes or cardiomyocyte cell lines as provided herein.

In some embodiments, the methods for determining the activity of acompound to inhibit hERG comprise: a) providing recombinantcardiomyocytes overexpressing hERG; b) contacting the cardiomyocyteswith a compound; c) measuring a test current (e.g., in a patch clampapparatus); and d) determining if the test current is reduced in thepresence of the compound, wherein a reduced test current is indicativeof hERG inhibitory activity. In some embodiments, the test current iscompared before and after contacting the recombinant cardiomyocytes withthe compound.

Provided herein are methods of screening compounds for cardiotoxicitycomprising using recombinant cardiomyocytes or cardiomyocyte cell linesas provided herein, including in methods for determining the activity ofcompounds to reduce cell viability.

In some embodiments, the methods for determining the activity ofcompounds to reduce cell viability comprise: a) providing recombinantcardiomyocytes overexpressing hERG; b) contacting the cardiomyocyteswith a compound in the presence of a viability indicator compound; c)measuring a signal of the indicator compound; and d) determining if thesignal is reduced or increased in the presence of the compound, whereina reduced or increased signal is indicative of reduced cell viability.In some embodiments, the signal is an absorbance, luminescence orfluorescence signal. In some embodiments, the signal is a fluorescencesignal. In some embodiments, the cell viability is compared before andafter contacting the recombinant cardiomyocytes with the compound.

In some embodiments, the recombinant cardiomyocytes or cardiomyocytecell lines used in the various methods as provided herein are designatedhMYO-hERG. Exemplary cells include those deposited as ATCC DesignationNo. PTA-123324, or progeny, derivatives, or descendants from the cells,including from culturing PTA-123324 cells to obtain progeny, derivative,or descendant cells.

Provided herein are methods of using the recombinant cardiomyocytes orcardiomyocyte cell lines as disclosed herein, or progeny, derivatives ordescendants from the recombinant cardiomyocytes or cardiomyocyte celllines, including from cells deposited as ATCC Designation No.PTA-123324, as disclosed herein. Such uses include drug screening forcardiotoxicity (e.g., hERG-related or non-hERG-related).

Provided herein are kits comprising the recombinant cells or cell linesas provided herein, including, for example, those designated ashMYO-hERG. In some embodiments, the kits comprise cells from the cellsdeposited as ATCC Designation No. PTA-123324, or progeny, derivatives ordescendants from the cells, including from culturing PTA-123324 cells toobtain progeny, derivative, or descendant cells.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a schematic representation depicting S1-S6 helices of hERG.

FIG. 2 shows the amino acid sequence of SEQ ID NO: 1 comprising anexemplary hERG amino acid sequence (see, e.g., amino acids 1-1159, asset forth in SEQ ID NO: 1). SEQ ID NO: 1 additionally comprises anexemplary linker amino acid sequence (see, e.g., amino acids 1160-1177as set forth in SEQ ID NO: 1) and an exemplary FLAG tag amino acidsequence (see, e.g., amino acids 1178-1185 as set forth in SEQ ID NO:1).

FIG. 3 shows SEQ ID NO: 2, nucleic acid sequence encoding amino acidsequence as set forth in SEQ ID NO: 1.

FIG. 4A shows an HIV based lentiviral vector carrying an exemplarynucleic acid sequence encoding hERG. FIGS. 4B-4C shows the expression ofhERG in the generated hMYO-hERG cells, HEK-hERG cells, and HeLa-hERGcells compared with control and other cell lines. In FIGS. 4B-4C, HEK,hMYO and HeLa are control cells. HEK-hERG, hMYO-hERG, HeLa-hERG arerecombinant cell lines that have been transduced with nucleic acidsequences encoding hERG. hMYO-Nav1.5-2 is a cell line expressing controlplasmids encoding a subunit of Nav1.5 ion channel (negative control forhERG ion channel). hMYO-Nav1.5-6 is a cell line expressing a subunit ofNav1.5 ion channel (negative control for hERG ion channel).

FIG. 5A shows an exemplary lonflux 16 plate that contains 8 experimentalregions (P1 to P8). FIG. 5B illustrates each region containing 12 wells.

FIG. 6 shows an exemplary voltage command protocol used for hERG currenton lonFlux16 automated patch clamp.

FIG. 7A shows currents of hMYO-hERG cells of passage No. 14 and thecurrents of hMYO cells (control without transfected or transduced hERG)at 37° C. FIG. 7B shows currents exhibited in the hMYO cells that didnot express hERG. FIG. 7C shows currents exhibited in the hMYO-hERGcells expressing hERG.

FIG. 8 shows currents of the hMYO-hERG cells of passage No. 17 at 37° C.

FIG. 9 shows currents of the hMYO-hERG cells of passage No. 25 at 37° C.

FIG. 10 shows block of hERG tail current by E-4031 in hMYO-hERG cells.

FIG. 11 shows block of hERG tail current by quinidine in hMYO-hERGcells.

FIG. 12A shows an exemplary determination of cell viability usingSetuBlue cell viability reagent: hMYO-hERG cells were plated in 96 wellplate and exposed to various concentration of control and testcompounds. Cells were assayed with Setublue reagent, incubated at 37° C.at standard culture conditions, and fluorescence was measured at 530/590using PerkinElmer EnSpire® multimode plate reader. FIG. 12B shows anexemplary CC₅₀ value as determined by locating the X-axis valuecorresponding to one-half the maximum (plateau) relative fluorescenceunit (RFU) value using GraphPad Prism software.

5. DETAILED DESCRIPTION 5.1 Definitions

As used herein, the term “human ERG,” “human ERG1,” “hERG” or “hERG1”refers to a human Ether-a-go-go-Related Gene of chromosome 7q36.1 thatcodes for a protein known as Kv11.1, the alpha (a) subunit of potassiumvoltage-gated channel, subfamily H (eag-related), member 2. It will beknown to those of ordinary skill in the art that hERG or hERG1 can bealso called different names, such as erg1, ERG1, KCNH2, Kv11.1, LQT2,and SQT1. See, e.g., “KCNH2 potassium voltage-gated channel, subfamily H(eag-related), member 2 [Homo sapiens (human)],” Gene ID: 3757, updated3 Nov. 2013, http://www.ncbi.nlm.nih.gov/gene/3757. As used herein, theterm “hERG” or “hERG1” refers interchangeably to the gene and theprotein known as Kv11.1 encoded by the gene. See also, e.g., “Potassiumvoltage-gated channel subfamily H member 2, Gene KCNH2, UniProtKb-Q12809 (KCNH2_human),” (http://www.uniprot.org/uniprot/Q12809). Anexemplary hERG polypeptide sequence is set forth in GenBank AccessionNumber BAA37096, and an exemplary hERG nucleic acid sequence is setforth in GenBank Accession Number SEG_AB00905S. In some embodiments, theamino acid sequence set forth in SEQ ID NO: 1 comprises a hERG aminoacid sequence (see, e.g., amino acids 1-1159 as set forth in SEQ ID NO:1).

As used herein, the term “hERG channel” refers to a potassiumvoltage-gated channel comprising Kv11.1, which is the alpha (a) subunitof the channel which forms a pore through a plasma membrane for passageof potassium ions across a plasma membrane.

As used herein, the term “protein” or “polypeptide” refers to anypolymer comprising amino acids, including any of the 20 naturallyoccurring amino acids, regardless of its size. The 20 naturallyoccurring amino acids may be classified into non-polar amino acids (Ala,lie, Leu, Met, Phe, Pro, Trp, Val), uncharged amino acids (Asn, Cys,Gln, Gly, Ser, Thr, Tyr), acidic amino acids (Asp, Glu), and basic aminoacids (Arg, His, Lys). Although “protein” is often used in reference torelatively large polypeptides, and “peptide” is often used in referenceto small polypeptides, usage of these terms in the art overlaps andvaries. The term “polypeptide” as used herein refers to peptides,polypeptides and proteins, unless otherwise noted. As used herein, theterms “protein”, “polypeptide” and “peptide” are used interchangeablyherein, for example, when referring to a gene product.

As used herein, the term “polynucleotide” refers to a polymer comprisinga plurality of bases, such as deoxyribonucleic acid (DNA) or ribonucleicacid (RNA), or base pairs, and includes DNA, cDNA, genomic DNA, andchemically synthesized DNA and RNA. Polynucleotides optionallycontaining non-natural bases are also included in the term“polynucleotide.” Specific examples of non-natural bases include4-acetylcytidine, 5-(carboxyhydroxylmethyl)uridine, 2′-O-methylcytidine,5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluridine, dihydrouridine,2′-O-methylpseudouridine, R-D-galactosylqueosine, 2′-O-methylguanosine,inosine, N6-isopentenyladenosine, 1-methyladenosine,1-methylpseudouridine, 1-methylguanosine, 1-methylinosine,2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine,3-methylcytidine, 5-methylcytidine, N6-methyladenosine,7-methylguanosine, 5-methylaminomethyluridine,5-methoxyaminomethyl-2-thiouridine, R-D-mannosylqueosine,5-methoxycarbonylmethyl-2-thiouridine, 5-methoxycarbonylmethyluridine,5-methoxyuridine, 2-methylthio-N-6-isopentenyladenosine,N-((9-β-D-ribofuranosyl-2-methyltiopurine-6-yl)carbamoyl)threonine,N-((9-β-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine,uridine-5-oxyacetic acid-methyl ester, uridine-5-oxyacetic acid,wybutoxosine, pseudouridine, queosine, 2-thiocytidine,5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine,N-((9-p-D-ribofuranosylpurine-6-yl)carbamoyl)threonime,2′-O-methyl-5-methyluridine, 2′-O-methyluridine, wybutosine and3-(3-amino-3-carboxypropyl)uridine.

As used herein, the term “exogenous nucleic acid sequence” refers to asequence originating from outside of a given cell. Such a sequence canbe introduced or transferred by genetic engineering into a cell or cellline, including by transformation, transfection, or transduction togenerate a recombinant cell or cell line. For example, as disclosedherein, an exogenous nucleic acid sequence encoding hERG is introducedor transferred by genetic engineering into a cardiomyocyte orcardiomyocyte cell line, including an immortalized cardiomyocyte orimmortalized cardiomyocyte cell line, to generate a recombinantcardiomyocyte or cardiomyocyte cell line. Such a recombinantcardiomyocyte or cardiomyocyte cell line, is designated herein as a“hERG-overexpressing cardiomyocyte” or a “hERG-overexpressingcardiomyocyte cell line”. As also disclosed herein, an exogenous nucleicacid sequence encoding hERG, useful for introduction or transfer bygenetic engineering into a cell or cell line, optionally comprisesadditional sequences including, for example, regulatory sequences,selectable marker sequences, and/or tag sequences. An exemplaryhERG-encoding nucleic acid sequence is set forth in FIG. 3 , andincludes a tag sequence (e.g., FLAG tag).

As used herein, the term “transformation” refers to a method by which anexogenous nucleic acid sequence is introduced or transferred into acell. In some embodiments, a cardiomyocyte is transformed with anexogenous nucleic acid sequence encoding hERG. The exogenous nucleicacid sequence encoding hERG optionally comprises additional sequencesincluding, for example, regulatory sequences, selectable markersequences, and/or tag sequences. Such a transformed cardiomyocyte isdesignated herein as a “hERG-overexpressing cardiomyocyte”.

As used herein, the term “transfection” refers to a method by which anexogenous nucleic acid sequence is introduced or transferred into a cellby non-viral means, such as, for example, through use of a non-viralvector. In some embodiments, a cardiomyocyte is transfected with anexogenous nucleic acid sequence encoding hERG through use of a non-viralvector. The exogenous nucleic acid sequence encoding hERG optionallycomprises additional sequences including, for example, regulatorysequences, selectable marker sequences, and/or tag sequences. Such atransfected cardiomyocyte is designated herein as a “hERG-overexpressingcardiomyocyte”.

As used herein, the term “transduction” refers to a method by which anexogenous nucleic acid sequence is introduced or transferred into a cellby viral means, such as, for example, through use of a viral vector. Insome embodiments, a cardiomyocyte is transfected with an exogenousnucleic acid sequence encoding hERG through use of a viral vector. Theexogenous nucleic acid sequence encoding hERG optionally comprisesadditional sequences including, for example, regulatory sequences,selectable marker sequences, and/or tag sequences. Such a transducedcardiomyocyte is designated herein as a “hERG-overexpressingcardiomyocyte”.

As used herein, the term “cell” refers not only to a given cell, butalso to progeny or potential progeny of such a cell, including animmortalized cell, for example, progeny, derivative, or descendant cellsof an immortalized cell. Exemplary cells include those deposited as ATCCDesignation No. PTA-123324, or progeny, derivatives, or descendants fromthe cells, including from culturing PTA-123324 cells to obtain progeny,derivative, or descendant cells. Because certain modifications can occurin succeeding generations due to either mutation or environmentalinfluences, such progeny might not, in fact, be identical to the parentcell, but are still included within the scope of the term as usedherein.

The term “cell line” refers to immortalized cells (e.g., a cellpopulation) that proliferate indefinitely. A cell line may be derivedfrom primary cells (e.g., a primary cell culture) by immortalizing thecells, for example, with SV40, hTERT, HPV E6/E7, EBV, MycT58A, RasV12,and p53. An exogenous nucleic acid sequence, including, for example, anexogenous nucleic acid sequence encoding hERG, can be introduced ortransferred by genetic engineering into a cell line, including bytransformation, transfection, or transduction. The exogenous nucleicacid sequence encoding hERG optionally comprises additional sequencesincluding, for example, regulatory sequences, selectable markersequences, and/or tag sequences. A “stable” cell line is a cell linethat exhibits substantially consistent characteristics over time (e.g.,as the cells proliferate in culture, for example, with each doubling, oras they are passaged). A stable cell line may be derived from a cellline that has been transformed, transfected, or transduced with anexogenous nucleic acid sequence, including, for example, an exogenousnucleic acid sequence encoding hERG. The exogenous nucleic acid sequenceencoding hERG optionally comprises additional sequences including, forexample, regulatory sequences, selectable marker sequences, and/or tagsequences.

The terms “progeny” and “descendants” as used herein refer to cellsobtained by culturing or otherwise growing a cell as described herein.Exemplary progeny or descendants are cells obtained by culturing cellsfrom those deposited as ATCC Designation No. PTA-123324.

The term “derivative” as used herein refers to a cell that is obtainedby modifying, for example, by fusing, transforming, transfecting,transducing, or otherwise changing a cell, including progeny ordescendants of the modified cell. Exemplary derivative cells are cellsobtained by culturing cells from those deposited as ATCC Designation No.PTA-123324, and modified, including by fusing, transforming,transfecting, transducing, or otherwise changing a cell.

As used herein, the term “host cell” refers to a cell into which anexogenous nucleic acid sequence has been introduced or transferred. Insome embodiments, host cells include, but are not limited to, mammaliancells (e.g., human cells such as cardiomyocytes).

As used herein, the term “expression,” and grammatical derivativesthereof, generally refers to the cellular processes by which apolypeptide is produced from RNA. For example, a hERG expressing cellproduces a hERG protein a hERG encoding nucleic acid sequence such as ahERG encoding RNA.

As used herein, “overexpression,” and grammatical derivatives thereof,refers to expression of a protein in a genetically engineeredcardiomyocyte (e.g., a recombinant cell) at levels above those normallyfound in the unengineered (e.g., parental) cardiomyocyte under the sameculture conditions (see, e.g., Example 2 and FIGS. 4B and 4C).

As used herein, the terms “hERG-overexpressing cells,”“hERG-overexpressing cell line,” “cardiomyocytes overexpressing hERG,”“cardiomyocyte cell line overexpressing hERG,” and the like, refers tocells or a cell line in which an exogenous nucleic acid sequenceencoding hERG is introduced or transferred by genetic engineering intothe cells or cell line, for example, cardiomyocytes or cardiomyocytecell line. Exemplary hERG-overexpressing cells are those designatedhMYO-hERG as disclosed herein (see, e.g., Example 2 and FIGS. 4B and4C). Additional exemplary hERG-overexpressing cells are cells obtainedfrom those deposited as ATCC Designation No. PTA-123324, including theirprogeny, descendants, or derivatives thereof.

As used herein, the term “cardiotoxic” or “cardiotoxicity” of a compoundrefers to cardiotoxicity of the compound in vitro, as measured by invitro activities of the compound, including hERG inhibitory activityand/or cell viability reduction activity. For example, as disclosedherein, methods for screening compounds for cardiotoxicity and/ormethods for determining cardiotoxicity of compounds determine thecardiotoxicity of the compounds by measuring the activity of thecompounds to inhibit hERG and/or by measuring the activity of thecompounds to reduce cell viability. Such in vitro methods of determiningcardiotoxicity are useful for predicting the risk of cardiotoxicity invivo. Cardiotoxicity of a compound in vivo refers to having a toxiceffect on the heart, for example, by a compound having a deleteriouseffect on the action of the heart, due to poisoning of the cardiacmuscle or of its conducting system. Cardiotoxicity can includefunctional cardiotoxicity (e.g., acute alteration of the mechanicalfunction of the myocardium) or structural cardiotoxicity (e.g.,morphological damage to cardiomyocytes or loss of cardiomyocyteviability). In some embodiments, long Q-T syndrome or “LQTS” is anaspect of cardiotoxicity (e.g., an aspect of functional cardiotoxicity).In some embodiments, loss of cell viability is an aspect ofcardiotoxicity (e.g., an aspect of structural cardiotoxicity). In someembodiments, a variety of cellular changes, for example, cytoskeletal,nuclear, mitochondrial, golgi and/or other subcellular compartmentchanges are aspects of morphological damage to cardiomyocytes (e.g.,aspects of structural cardiotoxicity).

As used herein, the term “reduced cardiotoxicity” of a compound refersto reduced cardiotoxicity of the compound in vitro. In some embodiments,a compound has reduced cardiotoxicity if it does not inhibit (e.g., byblocking or obstructing, either fully or partially) hERG. In someembodiments, a compound has reduced cardiotoxicity if it does not reducecardiomyocyte viability.

As used herein, the term “cell viability,” for example, as measured bycell death, lack of cell division, or cell dysfunction, refers to theability of the cell to maintain metabolic capacity, proliferate, and/ormaintain integrity of cell membranes, as measured, for example, by aviability assay. Exemplary viability assays include an ATP/ADP assay; aCalcein AM assay; a clonogenic assay; an ethidium homodimer assay; acytochrome oxidase activity assay; an adenylate kinase (AK) assay; anAlamar Dye/Setublue assay; a lactate dehydrogenase (LDH) assay;formazan-based assays (MTT/XTT); reduction of MTS tetrazolium; dyes suchas, e.g., Evans blue, neutral red, methyl violet, propidium iodide,sulforhodamine B, fluorescein diacetate hydrolysis/Propidium iodidestaining (FDA/PI staining), carboxyfluorosuccinimide ester (CFSE) dye,Resazurin, Trypan Blue, and a living-cell exclusion dye (dye onlycrosses cell membranes of dead cells)); detection of mutations in mtDNA;release of components across the mitochondrial permeability transitionpore; changes in mitochondrial membrane potential; flow cytometry; greenfluorescent protein; a DNA stain that can differentiate necrotic,apoptotic and normal cells; measurement of cytochrome c release; caspaseproteolytic cleavage of poly(ADP-ribose) polymerase (PARP); detection ofAnnexin V; senescence-associated expression of β-galactosidase(SA-β-Gal) activity; a TUNEL assay; and the like One of ordinary skillin the art will understand that the parameters that define cellviability in a particular assay can be diverse, for example, as theredox potential of the cell population, the integrity of cell membranes,or the activity of certain cellular enzymes. Each assay provides adifferent snapshot of cell health, and can individually or together formthe basis of an assay for cell viability. For example, cardiotoxicity ofa test compound can be measured in methods using recombinantcardiomyocytes or cardiomyocyte cell lines as provided herein, bymeasuring cell viability in the presence of the test compound and aviability indicator compound, wherein a reduction in cell viability inthe presence of the test compound is detected by measuring a signal fromthe indicator compound, wherein the signal of the indicator compound isincreased or decreased in the presence of the test compound, wherein areduction or increase in the signal is indicative of reduced cellviability. Reduction in cell viability may be measured when a compoundis cytotoxic or cytostatic.

As used herein, the term “reduced cell viability” with reference tocells, including cardiomyocytes, refers to a change in the value of ameasured parameter, for example, that indicates cell death, lack of celldivision, mitochondrial disruption, calcium dyshomeostasis, and/ordecrease in cellular ATP content in the cells, including cardiomycytes,for example, when the cardiomyocytes are contacted with a compound. Oneof ordinary skill in the art will understand that such changes can beaccompanied by mitochondrial membrane potential, loss of endoplasmicreticulum integrity, increased Ca²⁺ mobilization, and ATP depletion inthe cells, including cardiomyocytes (see, e.g., Pointon et al. (2013)Toxicol Sci. 132(2): 317-26).

As used herein, the term “ion channel” or “ion channel protein,” refersto a membrane bound protein that acts as a pore in a cell membrane andpermits the selective passage of ions (such as potassium ions), by meansof which electrical current passes in and out of the cell, such as ahERG channel.

As used herein, the term “potassium ion channel” or “potassium ionchannel protein,” refers to an ion channel that permits the selectivepassage of potassium ions (K⁺), such as a hERG channel.

As used herein, the term “hERG activity” refers to any observable effectflowing from hERG channel operation (e.g., passage and/or movementand/or flux of potassium (K⁺) ions across a plasma membrane). Arepresentative, but non-limiting, example of hERG activity in thecontext of the present disclosure includes conducting electricalcurrent, by passage and/or movement and/or flux of potassium (K⁺) ionsout of the cell across the plasma membrane.

As used herein, the terms “hERG inhibitory activity” or “hERG currentinhibitory activity” are used interchangeably, and refer to the activityof a compound to inhibit (e.g., by blocking or obstructing, eitherfullyor partially) a hERG channel, for example, by inhibiting passage and/ormovement and/or flux of potassium (K⁺) ions across a plasma membrane. Asdescribed herein, ion passage and/or movement and/or flux through a hERGchannel are detected as currents, for example, as detected by a patchclamp technique, as disclosed herein. For example, hERG inhibitoryactivity of a compound, that is, the activity of a compound to inhibithERG, can be measured in methods using recombinant cardiomyocytes orcardiomyocyte cell lines as provided herein by measuring current in thepresence of the compound, wherein a reduction in current in the presenceof the compound indicates hERG inhibitory activity.

As used herein, the term “compound” and “drug” are used interchangeably,and refer to any small molecule which is capable of binding to a targetreceptor, for example, hERG1. In some embodiments, the compound inhibitshERG activity. In some embodiments, if a compound or drug inhibits hERGactivity, the compound or drug may be referred to as a blocker.

As used herein, “high throughput screening” refers to a method thatallows a researcher to quickly conduct chemical, genetic orpharmacological tests, the results of which provide starting points fordrug design and for understanding the interaction or role of aparticular biochemical process in biology. For example, as disclosedherein, methods for screening compounds for cardiotoxicity, and/ormethods for determining cardiotoxicity of compounds, for example,measure the activity of the compounds to inhibit hERG and/or theactivity of the compounds to reduce cell viability, and are useful ashigh throughput screening methods.

As used herein, “electrophysiology techniques” refers to the use ofelectrophysiology measurements to measure voltage change or electriccurrent on a wide variety of scales, including single ion channelproteins. Electrophysiology techniques include electrical recordingtechniques that enable the measurement of the flow of ions (as measuredby ion current), including in in vitro assays with cells. For example,as disclosed herein, methods for determining the activity of compoundsto inhibit hERG, for example, by measuring currents, may useelectrophysiology techniques, including patch clamp techniques.

As used herein, “patch clamp technique” refers to use ofelectrophysiology measurements to detect the passage and/or movementand/or flux of ions through ion channels present on cell membranes withhigh sensitivity. The passage and/or movement and/or flux of ionsthrough ion channels present on cell surfaces are detected as currents.As used herein, the terms “patch clamp technique,” “ion flux technique,”“patch clamping,” “voltage clamping,” “electrophysiology measurements,”“patch clamp electrophysiology measurements,” and the like, are usedinterchangeably to refer to “patch clamp technique.” Patch clamptechnique are useful to measure hERG inhibitory activity in methods asdisclosed herein.

As used herein, the term “determine” and grammatical derivatives thereofmean qualitative and/or quantitative determinations, including measuringcurrent, voltage, and the like.

As used herein, the term “modulate” refers to an increase, decrease, orother alteration of any, or all, chemical and biological activities orproperties of a hERG polypeptide. The term “modulation” as used hereinrefers to both upregulation (e.g., activation or stimulation) anddownregulation (e.g., inhibition or suppression) of a response.

5.2 Embodiments

Provided herein are genetically engineered (e.g., transfected ortransduced) hERG-expressing cells or cell lines comprising recombinanthuman cardiomyocytes and cell lines overexpressing hERG. Also providedherein are methods of preparing recombinant cardiomyocytes orcardiomyocyte cell lines overexpressing hERG, including cardiomyocytestransduced with a vector encoding hERG. Further provided herein aremethods of using recombinant cardiomyocytes or cardiomyocyte cell lines.

Provided herein are recombinant cardiomyocytes and recombinant celllines overexpressing hERG and uses thereof. The recombinantcardiomyocytes or cardiomyocyte cell lines are more physiologicallyrelevant in methods for determining cardiotoxicity, includingdrug-induced cardiotoxicity, than other cells and cell lines such asChinese hamster ovary (CHO) or human embryonic kidney (HEK). Suchrecombinant cardiomyocytes or cardiomyocyte cell lines are alsoadvantageous as compared with primary cells and cell cultures (e.g.,primary cardiac cells, primary stem cells, etc.) in methods fordetermining cardiotoxicity, including drug-induced cardiotoxicity

Recombinant cardiomyocytes or cardiomyocyte cell lines, as providedherein, are particularly advantageous in methods for determiningcardiotoxicity, including drug-induced cardiotoxicity, because theypossess multiple utilities, including to assess toxicity as well asmechanisms of toxicity as measured, for example, by (i) hERG inhibitoryactivity, (ii) reduction in cell viability, and (iii) ultrastructuralchanges in cells, including, for example, changes to cytoskeleton,nucleus, mitochondria, golgi, and other subcellular compartments. Thus,a hERG-overexpressing cell line (e.g., cells from those deposited asATCC Designation No. PTA-123324, or progeny, derivatives, or descendantsfrom the cells, including from culturing PTA-123324 cells to obtainprogeny, derivative, or descendant cells) is simultaneously useful invarious assays to measure not only hERG inhibitory activities andreductions in cell viability, but also cell ultrastructural changes toassess mechanisms of toxicity. The use of such a cell line presents amore efficient and economical way of assessing cardiotoxicity, includingdrug-induced cardiotoxicity.

Recombinant cardiomyocytes or cardiomyocyte cell lines, as providedherein, have many advantages for identifying compounds with hERGinhibitory activity. The recombinant cardiomyocytes or cardiomyocytecell lines as provided herein perform well using electrophysiologytechniques, including manual patch clamping and high throughputautomated patch clamping to test current. Moreover, the recombinantcardiomyocytes or cardiomyocyte cell lines as provided herein performwell over a surprisingly wide range of temperatures ranging fromphysiological temperature to room temperature (e.g., 37° C. and 25° C.).The IKr current in the present recombinant cardiomyocytes orcardiomyocyte cell lines are unexpectedly useful for testing atphysiological temperature.

5.2.1. hERG Polypeptides and hERG Genes

The hERG1 ion channel (also referred to as KCNH2 or Kv11.1) is a keyelement for the rapid component of the delayed rectified potassiumcurrents (I_(Kr)) in cardiac myocytes, required for the normalrepolarization phase of the cardiac action potential (Curran et al.(1995) Cell 80: 795-803; Tseng (2001) J. Mol. Cell. Cardiol. 33: 835-49;Vandenberg et al. (2001) Trends. Pharm. Sci. 22: 240-246). Loss offunction mutations in hERG1 cause increased duration of ventricularrepolarization, which leads to prolongation of the time interval betweenQ and T waves of the body surface electrocardiogram (long QTsyndrome-LQTS) (Splawski et al. (2000) Circulation 102: 1178-1185;Witchel et al. (2000) Clin. Exp. Pharmacol. Physiol. 27: 753-766). LQTSleads to serious cardiovascular disorders, such as tachyarrhythmia andsudden cardiac death.

A human form of the erg gene, hERG (Genbank Accession Number U04270),which encodes hERG potassium ion channel subunits was first described byWarmke & Ganetzky (Warmke & Ganetzky (1994) Proc. Natl. Acad. Sci.U.S.A. 91: 3438-3442), incorporated herein by reference. An exemplaryhERG polypeptide sequence is set forth in GenBank Accession NumberBAA37096, and an exemplary hERG nucleic acid sequence is set forth inGenBank Accession Number SEG_AB00905S.

HERG channel may comprise four identical monomer α-subunits, which formthe channel's pore through the plasma membrane. Such a hERG tetramer isformed by coassembly of four monomer α-subunits, each of which has sixtransmembrane spanning α-helical segments (S1-S6), a pore helix situatedbetween S5 and S6, and cytoplasmically located N- and C-termini. Withineach hERG subunit, S1-S4 helices form a voltage sensor domain (VSD) thatsenses transmembrane potential and is coupled to a central K⁺-selectivepore domain (see, e.g., FIG. 1 ). Each pore domain is comprised of anouter helix (S5) and inner helix (S6) that together coordinate a porehelix and selectivity filter. The carboxy end of the pore helix andselectivity filter contain a highly conserved K channel signaturesequence, which in hERG is Thr-Ser-Val-Gly-Phe-Gly. This sequence formsa narrow conduction pathway at the extracellular end of the pore inwhich K ions are coordinated by a backbone carbonyl oxygen atoms of thesignature sequence residues.

Movements of the voltage-sensor domain enable a pore domain to open andclose in response to changes in membrane potential. A drug binding siteis contained within the central pore cavity of the pore domain, locatedbelow the selectivity filter and flanked by the four S6 helices of thetetrameric channel. Without being limited by any theory, inhibiting byblocking or obstructing, either fully or partially, of a central porecavity or channel of hERG by a compound is a predictor of cardiotoxicityof the compound. Undesired blockade of K⁺ ion flux in hERG by a compoundcan lead to long QT syndrome, eventually inducing fibrillation andarrhythmia. Long QT syndrome is a group of disorders that increase therisk for sudden death due to an abnormal heartbeat. The QT refers to aninterval between two points (Q and T) on the common electrocardiogram(ECG, EKG) used to record the electrical activity of the heart. Thiselectrical activity, in turn, is the result of ions such as sodium andpotassium passing through ion channels in the membranes surroundingheart cells. A prolonged QT interval indicates an abnormality inelectrical activity that leads to irregularities in heart musclecontraction. One of these irregularities is a specific pattern of veryrapid contractions (tachycardia) of the lower chambers of the heartcalled torsade de pointes, a type of ventricular tachycardia. The rapidcontractions, which are not effective in pumping blood to the body,result in a decreased flow of oxygen-rich blood to the brain. This canresult in a sudden loss of consciousness (syncope) and death. hERGblockade is a significant problem experienced during the course of manydrug discovery and/or drug development programs.

In some embodiments, a hERG gene as provided herein is the hERG gene ofchromosome 7q36.1. In some embodiments, a hERG polypeptide sequence tobe expressed in recombinant cardiomyocytes comprises a polypeptidecomprising an amino acid sequence identical or substantially identicalwith amino acids 1-1159 of the amino acid sequence as set forth in SEQID NO: 1 (see, e.g., FIG. 2 ). In some embodiments, a hERG polypeptidesequence comprises an amino acid sequence identical or substantiallyidentical to the amino acid sequence as set forth in SEQ ID NO: 1, whichincludes a tag sequence. The sequence optionally includes a linkersequence, as shown in FIG. 2 . In some embodiments, a hERG polypeptidesequence optionally comprises additional sequences including, forexample, regulatory sequences, selectable marker sequences, and/or tagsequences. In some embodiments, an amino acid sequence substantiallyidentical with the amino acid sequence as set forth in SEQ ID NO: 1, oroptionally with amino acids 1-1159 of the amino acid sequence as setforth in SEQ ID NO: 1, has an amino acid sequence of about 90% or moreidentity with the amino acid sequence as set forth in SEQ ID NO: 1, oroptionally with amino acids 1-1159 of the amino acid sequence as setforth in SEQ ID NO: 1, wherein the polypeptide has hERG activity. Insome embodiments, an amino acid sequence substantially identical withthe amino acid sequence as set forth in SEQ ID NO: 1, or optionally withamino acids 1-1159 of the amino acid sequence as set forth in SEQ ID NO:1, has an amino acid sequence of about 95% or more identity with theamino acid sequence as set forth in SEQ ID NO: 1, or optionally withamino acids 1-1159 of the amino acid sequence as set forth in SEQ ID NO:1, wherein the polypeptide has hERG activity. In some embodiments, anamino acid sequence substantially identical with the amino acid sequenceas set forth in SEQ ID NO: 1, or optionally with amino acids 1-1159 ofthe amino acid sequence as set forth in SEQ ID NO: 1, has an amino acidsequence of about 98% or more identity with the amino acid sequence asset forth in SEQ ID NO: 1, or optionally with amino acids 1-1159 of theamino acid sequence as set forth in SEQ ID NO: 1, wherein thepolypeptide has hERG activity. An exemplary amino acid sequencesubstantially identical with the amino acid sequence as set forth in SEQID NO: 1, or optionally with amino acids 1-1159 of the amino acidsequence as set forth in SEQ ID NO: 1, has an amino acid sequence ofabout 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity withthe amino acid sequence as set forth in SEQ ID NO: 1, or optionally withamino acids 1-1159 of the amino acid sequence as set forth in SEQ ID NO:1, wherein the polypeptide has hERG activity. In some embodiments,examples of the amino acid sequence substantially identical with theamino acid sequence as set forth in SEQ ID NO: 1, or optionally withamino acids 1-1159 of the amino acid sequence as set forth in SEQ ID NO:1, include an amino acid sequence having mutations such as deletion,substitution or addition in one or a plurality of (e.g., one or more)amino acids, wherein the polypeptide has hERG activity.

In some embodiments, a hERG polypeptide sequence to be expressed inrecombinant cardiomyocytes or cardiomyocyte cell lines as providedherein comprises a polypeptide comprising an amino acid sequence as setforth in SEQ ID NO: 1 which has mutations such as deletion, substitutionor addition in one or a plurality of (e.g., one or more) amino acids, ora combination thereof. In some embodiments, a hERG polypeptide sequenceto be expressed in recombinant cardiomyocytes or cardiomyocyte celllines as provided herein comprises a polypeptide comprising an aminoacid sequence as set forth in SEQ ID NO: 1 in which one to five aminoacids are deleted. In some embodiments, a hERG polypeptide sequence tobe expressed in recombinant cardiomyocytes or cardiomyocyte cell linesoverexpressing hERG as provided herein comprises a polypeptidecomprising an amino acid sequence as set forth in SEQ ID NO: 1 to whichone to five amino acids are added. In some embodiments, a hERGpolypeptide sequence to be expressed in recombinant cardiomyocytes orcardiomyocyte cell lines overexpressing hERG as provided hereincomprises a polypeptide comprising an amino acid sequence as set forthin SEQ ID NO: 1 into which one to five amino acids are inserted. In someembodiments, a hERG polypeptide sequence to be expressed in humancardiomyocytes comprise a polypeptide comprising an amino acid sequenceas set forth in SEQ ID NO: 1 in which one to five amino acids aresubstituted with other amino acids. A mutant polypeptide comprising anamino acid sequence having deletion, insertion, substitution or additionof one or a plurality of amino acids and retains the same biologicalactivity of the original (e.g., non-mutated) polypeptide is alsoincluded in the scope of the present disclosure. A mutant hERG maycomprise such a mutant polypeptide.

Substitution of amino acids refers to a mutation in which one or moreamino acid residues in an amino acid sequence are replaced with otheramino acids. In some embodiments, a conservative substitution is made inan modification of the amino acid sequence encoded by the hERG gene. Aconservative substitution refers to a change in a sequence so that thechanged sequence encodes an amino acid similar to the replaced aminoacid. Amino acids may be classified into non-polar amino acids (Ala,lie, Leu, Met, Phe, Pro, Trp, Val), uncharged amino acids (Asn, Cys,Gln, Gly, Ser, Thr, Tyr), acidic amino acids (Asp, Glu), basic aminoacids (Arg, His, Lys), neutral amino acids (Ala, Asn, Cys, Gln, Gly,lie, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val), aliphatic amino acids(Ala, Gly), branched amino acids (lie, Leu, Val), hydroxylamino acids(Ser. Thr), amidic amino acids (Gln, Asn), sulfo-amino acids (Cys, Met),aromatic amino acids (His, Phe, Trp, Tyr), heterocyclic amino acids(His, Trp), imino acids (Pro, 4Hyp) and so on. For example,substitutions between Ala, Val, Leu and lie, between Ser and Thr,between Asp and Glu, between Asn and Gln, between Lys and Arg, andbetween Phe and Tyr can be used for retaining the nature of the protein.The number and sites of amino acids to be mutated are not particularlylimited.

Polynucleotides encoding an amino acid sequence as set forth in SEQ IDNO: 1 having deletion, insertion, substitution or addition of one or aplurality of amino acids can be prepared according to methods such assite-specific mutagenesis described, for example, in “Molecular Cloning,A Laboratory Manual 2nd ed.” (Cold Spring Harbor Press (1989)), “CurrentProtocols in Molecular Biology” (John Wiley & Sons (1987-1997);especially in Section 8.1-8.5), Hashimoto-Goto et al. (1995) Gene 152:271-5, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82: 488-92, Kramer andFritz (1987) Method. Enzymol. 154: 350-67, and Kunkel (1988) Method.Enzymol. 85: 2763-6.

Introduction of mutations into polynucleotides may be performed by knownmethods such as the Kunkel method or the Gapped duplex method using, forexample, QuikChange™ Site-Directed Mutagenesis Kit (Stratagene),GeneTailor™ Site-Directed Mutagenesis System (Invitrogen), or TaKaRaSite-Directed Mutagenesis System (In-Fusion® HD Mutagenesis, Mutan-K,Mutan-Super Express Km).

Amino acid residues composing a polypeptide as provided herein may beeither naturally occurring amino acid residues or modified amino acidresidues. Specific examples of modification of amino acid residuesinclude acylation, acetylation, amidation, arginylation, GPI anchorformation, cross-linking, γ-carboxylation, cyclization, formation ofcovalent bridges, glycosylation, oxidation, covalent bonding to lipid orfat derivatives, formation of disulfide bonds, selenoylation,demethylation, degradation treatment of proteins, covalent bonding tonucleotides or nucleotide derivatives, hydroxylation, formation ofpyroglutamate, covalent bonding to flavin, prenylation, covalent bondingto heme moieties, covalent bonding to phosphatidylinositol, formylation,myristoylation, methylation, ubiquitination, iodination, racemization,ADP-ribosylation, sulfation and phosphorylation.

In some embodiments, a polypeptide as provided herein encompasses fusionproteins where other peptide sequences have been added. Peptidesequences to be added to a polypeptide comprising tag sequences asprovided herein (e.g., FLAG tag) may be selected from sequences thatmake discrimination of a fusion protein easy or sequences that givestability when a fusion protein is expressed by recombinant DNAtechnology (e.g., influenza hemagglutinin (HA), glutathione Stransferase (GST), substance P, multiple histidine tag (6×His, 10×His,etc.), protein C fragment, maltose binding protein (MBP), immunoglobulinconstant region fragment, α-tubulin fragment, β-galactosidase, B-tag,c-myc fragment, E-tag (epitope on monoclonal phage), FLAG (Hopp et al.(1988) Bio/Technol. 6: 1204-10), Ick tag, p18 HIV fragment, HSV-tag(human herpes simplex virus glycoprotein), SV40T antigen fragment,T7-tag (T7 gene10 protein), VSV-GP fragment (Vesicular stomatitis virusglycoprotein), etc).

In some embodiments, a polypeptide as provided herein is a polypeptidewhich comprises an amino acid sequence as set forth in SEQ ID NO: 1(alternatively, amino acids 1-1159 of the amino acid sequence as setforth in SEQ ID NO: 1), or an amino acid sequence substantiallyidentical with the amino acid sequence as set forth in SEQ ID NO: 1(alternatively, amino acids 1-1159 of the amino acid sequence as setforth in SEQ ID NO: 1), and has a hERG activity substantially identical(e.g., physiochemically or pharmacologically) with the hERG activitypossessed by a polypeptide comprising the amino acid sequence as setforth in SEQ ID NO: 1 (alternatively, amino acids 1-1159 of the aminoacid sequence as set forth in SEQ ID NO: 1). A hERG gene refers to apolynucleotide comprising a nucleic acid sequence encoding hERG. A hERGgene as provided herein encompasses a polynucleotide comprising anucleic acid sequence identical or substantially identical with thenucleic acid sequence as set forth in SEQ ID NO: 2 (GenBank AccessionNo. U04270 and see FIG. 3 ). For example, in addition to polynucleotidesencoding the amino acid sequence as set forth in SEQ ID NO: 2, apolynucleotide encoding a mutant polypeptide comprising an amino acidsequence as set forth in SEQ ID NO: 1 having deletion, insertion,substitution or addition of one or plurality of amino acids and has hERGactivity may also be used.

A hERG gene as provided herein encompasses genetic polymorphisms of anucleic acid sequence as set forth in SEQ ID NO: 2. A geneticpolymorphism may be easily known by using databases such as GenBank(http://www.ncbi.nlm.nih.gov). Genetic polymorphism includes singlenucleotide polymorphism (SNP) and polymorphism caused by a varied numberof nucleic acid sequence repeats. Polymorphism caused by deletion orinsertion of a plurality of nucleotides (e.g., two to several tens ofnucleotides) is also included in genetic polymorphism. For example,polymorphism where a sequence of two to several tens of nucleotides isrepeated is also included in genetic polymorphism. Examples ofpolymorphisms include VNTR (variable number of tandem repeat) (repeatunit composed of several to several tens of nucleotides) andmicro-satellite polymorphism (repeat unit composed of about two to fournucleotides).

In some embodiments, a hERG gene as provided herein includes a nucleicacid sequence encoding an amino acid sequence as set forth in SEQ ID NO:2. A nucleic acid sequence encoding such an amino acid sequenceencompasses, in addition to the nucleic acid sequence as set forth inSEQ ID NO: 2, nucleic acid sequences which are different from SEQ ID NO:2, for example, due to degeneracy of the genetic code. A nucleic acidsequence as set forth in SEQ ID NO: 2 from which non-coding regions areremoved may also be used. When a polynucleotide as provided herein isused for expressing a polypeptide by genetic engineering techniques, anucleic acid sequence with high expression efficiency may be selectedand designed in view of codon usage frequency in a cell to be used forexpression (Grantham et al. (1981) Nucleic Acids Res. 9: 43-74).

In some embodiments, a hERG gene as provided herein encompasses apolynucleotide that hybridizes to a nucleic acid sequence as set forthin SEQ ID NO: 2 or a sequence complementary thereto under stringentconditions and encodes a polypeptide having hERG activity. Examples ofsuch a polynucleotide include isoforms, alternative isoforms and allelicmutants, these are included in a hERG gene as provided herein. Such hERGgenes may be obtained from human cDNA libraries or genomic libraries bya known hybridization method, such as colony hybridization, plaquehybridization or Southern blotting, using a polynucleotide comprisingthe nucleic acid sequence as set forth in SEQ ID NO: 2 or a fragmentthereof as a probe. For methods for preparing cDNA libraries, see“Molecular Cloning, A Laboratory Manual 2nd Ed.” (Cold Spring HarborPress (1989)). Alternatively, commercial cDNA libraries or genomiclibraries may be used.

In some embodiments, preparation of a cDNA library can be performed asfollows: total RNA is prepared from a cell, organ or tissue that isexpressing a hERG gene as provided herein by a known method such as theguanidine ultracentrifugation method (Chirwin et al. (1979) Biochemistry18: 5294-9) or the AGPC method (Chomczynski and Sacchi (1987) Anal.Biochem. 162: 156-9). Then, mRNA can be purified therefrom by using mRNAPurification Kit (Pharmacia) or the like. Alternatively, a kit such asQuick Prep mRNA Purification Kit (Pharmacia) can be used to prepare mRNAdirectly from cells, organs or tissues. Subsequently, cDNA can besynthesized from the resultant mRNA with a reverse transcriptase. A cDNAsynthesis kit such as AMV Reverse Transcriptase First-Strand cDNASynthesis Kit (Seikagaku Corporation) can also be used. Alternatively,cDNA can be synthesized and amplified by 5′-RACE method utilizing PCR(Frohman et al. (1988) Proc. Natl. Acad. Sci. USA 85: 8998-9002;Belyavsky et al. (1989) Nucleic Acids Res. 17: 2919-32). It is alsopossible to employ a known technique such as oligo-capping method(Maruyama and Sugano (1994) Gene 138: 171-4; Suzuki (1997) Gene 200:149-56) in order to prepare a cDNA library with a high full-length cDNAratio. A cDNA obtained as described above can be incorporated into anappropriate vector. cDNA can be also synthesized directly byconcatenating oligo nucleotide sequences.

Stringent conditions as provided herein can be, for example, (2×SSC,0.1% SDS, 50° C.), (2×SSC, 0.1% SDS, 42° C.) or (1×SSC, 0.1% SDS, 37°C.); more stringent conditions can be, for example, (2×SSC, 0.1% SDS,65° C.), (0.5×SSC, 0.1% SDS, 42° C.) or (0.2×SSC, 0.1% SDS, 65° C.).More specifically, hybridization using Rapid-hyb buffer (Amersham LifeScience) can be performed as described below, for example.Pre-hybridization can be performed at 68° C. for more than 30 min; then,a probe can be added to a hybridization solution, which is retained at68° C. for more than 1 hr to allow hybrid formation; then, washing canbe carried out in 2×SSC, 0.1% SDS at room temperature for 20 min threetimes, in 1×SSC, 0.1% SDS at 37° C. for 20 min three times, and finallyin 1×SSC, 0.1% SDS at 50° C. for 20 min two times. Alternatively, forexample, pre-hybridization can be performed in ExpressHyb™ HybridizationSolution (CLONTECH) at 55° C. for more than 30 min; a labeled probe canbe added to the solution, which is incubated at 37-55° C. for more than1 hr; then, washing can be carried out in 2×SSC, 0.1% SDS at roomtemperature for 20 min three times and in 1×SSC, 0.1% SDS at 37° C. for20 min once. It is possible to make hybridization conditions morestringent, for example, by raising the temperature of pre-hybridization,hybridization or second washing. For example, it is possible to settemperature of pre-hybridization and hybridization at 60° C., or at 68°C. for more stringent conditions. Those skilled in the art canappropriately select salt concentration and temperature of a buffer, aswell as concentration and length of a probe, reaction time, etc., tothereby set conditions for obtaining polynucleotides encoding a hERGgene as provided herein.

For detailed procedures of hybridization, see “Molecular Cloning, ALaboratory Manual 2nd ed.” (Cold Spring Harbor Press (1989); especiallySection 9.47-9.58), “Current Protocols in Molecular Biology” (John Wiley& Sons (1987-1997); especially Section 6.3-6.4), “DNA Cloning 1: CoreTechniques, A Practical Approach 2nd ed.” (Oxford University (1995);especially, see Section 2.10 for conditions), and so forth. Examples ofpolynucleotides which hybridize to a nucleic acid sequence as set forthin SEQ ID NO: 2 or a sequence complementary thereto includepolynucleotides comprising a nucleic acid sequence having 50% or more,preferably 70% or more, more preferably 80% or more, still morepreferably 90% or more (e.g., 95% or more, or 99% or more) identity tothe nucleic acid sequence as set forth in SEQ ID NO: 2. Such identitycan be determined with BLAST algorithm (Altschul, (1990) Proc. Natl.Acad. Sci. USA 87: 2264-8; Karlin and Altschul, (1993) Proc. Natl. Acad.Sci. USA 90: 5873-7). Among programs based on this algorithm, there areprograms for determining identity in sequences. BLASTX for amino acidsequence and BLASTN (Altschul et al. (1990) J. Mol. Biol. 215: 403-10)for nucleic acid sequences have been developed and are available to thesequences of the present disclosure. For specific analyzing methods,see, for example, http://www.ncbi.nlm.nih.gov.

Genes whose structure and function are similar to those of hERG, such asisoforms or allelic mutants of hERG, (such genes are included in a hERGgene as provided herein) may be obtained from human cDNA library orgenomic library by using primers designed based on a nucleic acidsequence as set forth in SEQ ID NO: 2 and a gene amplification technique(PCR) (Current Protocols in Molecular Biology, John Wiley & Sons (1987)Section 6.1-6.4).

Polynucleotides as provided herein encompass polynucleotides encoding anamino acid sequence as set forth in SEQ ID NO: 2 having deletion,insertion, substitution or addition of one or a plurality of aminoacids, or sequences complementary to the sequences of thesepolynucleotides. These polynucleotides of the present disclosure can beprepared according to the site-specific mutagenesis method or the likedescribed in “Molecular Cloning, A Laboratory Manual 2nd ed.” (ColdSpring Harbor Press (1989)), “Current Protocols in Molecular Biology”(John Wiley & Sons (1987-1997); especially Section 8.1-8.5),Hashimoto-Goto et al. (1995) Gene 152: 271-5, Kunkel (1985) Proc. Natl.Acad. Sci. USA 82: 488-92, Kramer and Fritz (1987) Method. Enzymol. 154:350-67, Kunkel (1988) Method. Enzymol. 85: 2763-6, etc. Commercial kitscan be used for mutagenesis.

Confirmation of a nucleic acid sequence of a polynucleotide as providedherein can be performed by sequencing using conventional methods. Forexample, the dideoxynucleotide chain termination method (Sanger et al.(1977) Proc. Natl. Acad. Sci. USA 74: 5463) can be used. Alternatively,a sequence can be analyzed with an appropriate DNA sequencer. In someembodiments, the sequencing methodology can be sequencing-by-synthesis(SBS). In SBS, extension of a nucleic acid primer along a nucleic acidtemplate (e.g. a target nucleic acid or amplicon thereof) can bemonitored to determine the sequence of nucleotides in the template. Theunderlying chemical process can be polymerization (e.g. as catalyzed bya polymerase enzyme). In a particular polymerase-based SBS embodiment,fluorescently labeled nucleotides can be added to a primer (therebyextending the primer) in a template dependent fashion such thatdetection of the order and type of nucleotides added to the primer canbe used to determine the sequence of the template.

Other sequencing procedures that use cyclic reactions can be used, suchas pyrosequencing. Pyrosequencing detects the release of inorganicpyrophosphate (PPi) as particular nucleotides are incorporated into anascent nucleic acid strand (Ronaghi et al. (1996) AnalyticalBiochemistry 242(1): 84-9; Ronaghi (2001) Genome Res. 11(1): 3-11;Ronaghi et al. (1998) Science 281(5375): 363; U.S. Pat. Nos. 6,210,891;6,258,568 and 6,274,320, each of which is incorporated herein byreference). In pyrosequencing, released PPi can be detected by beingimmediately converted to adenosine triphosphate (ATP) by ATPsulfurylase, and the level of ATP generated can be detected vialuciferase-produced photons. Thus, the sequencing reaction can bemonitored via a luminescence detection system. Excitation radiationsources used for fluorescence based detection systems are not necessaryfor pyrosequencing procedures. Useful fluidic systems, detectors andprocedures that can be adapted for application of pyrosequencing toamplicons produced according to the present disclosure are described,for example, in PCT/US11/57111, US 2005/0191698 A1, U.S. Pat. Nos.7,595,883, and 7,244,559, each of which is incorporated herein byreference.

5.2.2. Vectors

In some embodiments, a nucleic acid representing at least part of a hERGgene has been transferred with a vector to human cardiomyocytes. Suchtransfer is referred to as transfection or transduction.

The type of vector used in the method is not limited. In someembodiments, the vector is a viral vector and the transfer is bytransduction. In some embodiments, the vector is a non-viral vector andthe transfer is by transfection. Non-viral transfection can befacilitated by a number of techniques, including without limitationelectroporation or the use of chemical transfection agents known in theart.

In some embodiments, viral vectors containing a hERG gene (e.g., anucleic acid sequence encoding hERG) are provided. In some embodiments,the viral vector used herein was engineered by using a virus-derivednucleic acid sequence so that it is capable of integrating any nucleicacid sequence into any cell. A viral vector is useful in retaining ahERG gene as provided herein within host cells and allowing expressionof a hERG polypeptide encoded by a hERG gene.

In some embodiments, the viral vector is a retroviral vector, such as alentiviral vector. Retrovirus refers to any virus belonging to the genusOncovirus in the subfamily Oncovirinae in the family Retroviridae, andlentivirus refers to any virus belonging to the genus Lentivirus in thesubfamily Lentivirinae in the family Retroviridae. In some embodiments,the viral vector is a lentiviral vector. In a some embodiments, anexemplary lentiviral vector as provided herein is shown in exemplaryFIG. 4A.

In some embodiments, a retroviral vector is a kind of recombinantretrovirus such as the Moloney murine leukemia virus. Moloney murineleukemia virus has the ability to integrate into the host genome in astable fashion, and contain a reverse transcriptase that allowsintegration into a host genome. In some embodiments, a retroviral vectoras provided herein is replication-competent. In some embodiments, aretrovial vector as provided herein is replication-defective. In someembodiments, replication defective retrovial vectors are used since theyare capable of infecting their target cells and delivering their viralpayload, but then fail to continue the typical lytic pathway that leadsto cell lysis and death.

In some embodiments, a viral vector is a lentiviral vector, which is asubclass of retroviral vectors. Lentiviral vectors have been adapted tointegrate into the genome of non-dividing cells. In some embodiments, aviral genome in the form of RNA is reverse-transcribed when the virusenters the cell to produce DNA, which is then inserted into a genome bythe viral integrase enzyme. Such as a vector can remain in the genomeand passed on to the progeny of the cell when it divides.

Exemplary retroviral vectors include, but not limited to, pZIPneo(Cepko, C. L. et al. (1984) Cell. 37: 1053-1062), pBabePuro(Morgenstern, J. P. and Land, H., Nucleic Acids Res. 18: 3587-3596),pCLXSN (IMGENEX, catalog #10041P), ViraPort retroviral gene expressionsystem (Stratagene, catalog #217563), pDON-AI (Takara, catalog #3650)and lentiviral vectors such as pLenti6/V5-GW/lacZ (Invitrogen, Carlsbad,Calif., catalog #K4955-10). In some embodiments, viral vectors preparedfrom viruses other than retrovirus and lentivirus may also be used,e.g., vectors prepared from adenovirus, adeno-associated virus, Sinbisvirus, Sendai virus, togavirus, paramyxovirus, poxvirus, poliovirus,herpesvirus and vaccinia virus.

In some embodiments, a retroviral vector is a Vesicular stomatitisvirus-G protein (VSV-G) pseudotyped retroviral vector. The term“pseudotyped” or “pseudo” refers to a phenomenon in which the genome ofone virus is budding surrounded by the envelope protein of other virus(Zavada (1972) J. Gen. Virol. 15: 183-191). Vesicular stomatitis virus(VSV) is a virus belonging to the family Rhabdoviridae and having anegative single-stranded RNA genome. It is believed that the receptor ofits envelope protein (G protein) on the cell side is an anionic lipidsuch as phosphatidylserine (Schlegel et al. (1983) Cell 32: 639-646;Mastromarino et al. (1987) J. Gen. Virol. 68: 2359-2369). It is reportedthat VSV-G pseudotyped retroviral vector has an extremely broad hostrange compared to conventionally used amphotropic retroviral vectors(Emi et al. (1991) Proc. Natl. Acad. Sci. USA. 65: 1202-1207; Arai etal. (1999) Virol. 260: 109-115) and that its gene transfer ability canbe improved by ultracentrifugation (Burns et al. (1993) Proc. Natl.Acad. Sci. USA, 90: 8033-8037). Therefore, by preparing a pseudotypedretrovirus having this VSV-G gene product as an envelope protein, itbecomes possible to transfer the hERG gene into various cells moreefficiently than achieved by retroviruses having their innate envelopeprotein. The nature of these VSV-G pseudotyped vectors is the same inlentiviral vectors, and a large number of lentiviral vectors reportedare pseudotyped vectors of this kind (Kay et al. (2001) Nature Med.7:33-40), and can be used in the present disclosure.

In some embodiments, a viral vector is linked to downstream region ofregulatory sequences so that it comes to enable the expression of a hERGgene as provided herein in a host cardiomyocyte cell into which theviral vector has been introduced. The “regulatory sequences” includepromoter and terminator, and optionally include trans-activator,transcription factor, poly-A signals that stabilizes transcript,splicing and polyadenylation signals, and the like. These regulatorysequences contain components necessary for expression of thepolynucleotide linked thereto.

In some embodiments, a viral vector as provided herein can containselectable markers. Exemplary selectable markers include drug resistancegenes (neomycin resistance gene, hygromycin resistance gene, puromycinresistance gene, etc.) and fluorescent proteins (GFP, EGFP, etc.). Insome embodiments, a signal peptide can be integrated that is useful fordirecting the intracellularly expressed polypeptide onto cell membranesinto a viral vector so that the signal peptide is added to thepolypeptide. Further, in some embodiments, addition of linker andinsertion of initiation codon (ATG) and termination codon (TAA, TAG orTGA) can be performed.

In some embodiments, when a mammalian cell or other animal cell is usedas a host, adenovirus late promoter (Kaufman et al. (1989) Mol. Cell.Biol. 9: 946), CAG promoter (Niwa et al. (1991) Gene 108: 193-200), CMVimmediate early promoter (Seed and Aruffo (1987) Proc. Natl. Acad. Sci.USA 84: 3365-9), EF1α promoter (Mizushima et al. (1990) Nucleic AcidsRes. 18: 5322; Kim et al. (1990) Gene 91: 217-23), HSV TK promoter, SRαpromoter (Takebe et al. (1988) Mol. Cell. Biol. 8: 466), SV40 promoter(Mulligan et al. (1979) Nature 277: 108), SV40 early promoter (GeneticEngineering Vol. 3, Williamson ed., Academic Press (1982) pp. 83-141),SV40 late promoter (Gheysen and Fiers (1982) J. Mol. Appl. Genet. 1:385-94), RSV (Rous sarcoma virus)-LTR promoter (Cullen (1987) MethodsEnzymol. 152: 684-704), MMLV-LTR promoter, CMV enhancer, SV40 enhancer,cPPT (central polypurine tract) sequence, globin intron, etc. may beused.

Insertion of a hERG gene into a viral vector can be performed by ligasereaction. Restriction enzyme sites can also be used (Current Protocolsin Molecular Biology, John Wiley & Sons (1987) Section 11.4-11.11;Molecular Cloning, A Laboratory Manual 2nd ed., Cold Spring Harbor Press(1989) Section 5.61-5.63).

In some embodiments, to produce a lentivirus, several vectors (e.g.,plasmids) can be transfected into a so-called packaging cell line, suchas HEK 293. For example, one or more plasmids, generally referred to aspackaging plasmids, encode virion proteins, such as the capsid and thereverse transcriptase. Another plasmid can contain the genetic materialto be delivered. In some embodiments, it can transcribed to produce asingle-stranded RNA viral genome and is marked by the presence of a ψ(psi) sequence. This sequence can be used to package the genome into thevirion.

The term “viral vector,” as used herein, refers to a vector (e.g.,plasmid) comprising viral sequences such as viral promoter sequences. Aviral vector, such as a lentiviral vector, can be introduced into apackaging cell. A packaging cell such as HEK 293 cell or the like can beused. A viral vector can be introduced into a packaging cell by variousmethods such as an adenovirus method, electroporation (Cytotechnology 3:133 (1990)), a cationic liposome method (cationic liposome DOTAP(Boehringer Mannheim), etc.), a method using a positively chargedpolymer, an electrostatic type liposome method, a internal type liposomemethod, particle gun bombardment, a liposome method, lipofection (Proc.Natl. Acad. Sci. USA 84: 7413 (1987) (e.g., lipofectamine 2000(Invitrogen), Fugene 6 (Roche Diagnostics), etc.)), a calcium phosphatemethod (JP 2-227075 A), receptor-mediated gene transfer, a retrovirusmethod, a DEAE dextran method, a virus-liposome method (ExperimentalMedicine additional volume “Basic Technology for Gene Therapy”, Yodo-sha(1997); Experimental Medicine additional volume “Analytical Experimentson Gene Transfer and Expression”, Yodo-sha (1997); J. Clin. Invest. 93:1458-64 (1994); Am. J. Physiol. 271: R1212-20 (1996); Molecular Medicine30: 1440-8 (1993); Experimental Medicine 12: 1822-6 (1994); Protein,Nucleic Acid and Enzyme 42: 1806-13 (1997); Circulation 92 (Suppl. II):479-82 (1995)) and direct transfer of naked-DNA. A commerciallyavailable viral vector packaging system can be used (e.g., a LentiPAK™lentiviral packaging system from GeneCopoeia as described in Example 1).

5.2.3. Cardiomyocyte as Host Cells

In some embodiments, a host cell that expresses hERG as provided hereinis a recombinant human cardiomyocyte. In some embodiments, a host cellthat expresses hERG as provided herein is a cell derived from humancardiomyocytes. Cardiomyocytes (also known as myocardiocytes or cardiacmyocytes) are the muscle cells (myocytes) that make up the cardiacmuscle. Each myocardial cell contains myofibrils, which are specializedorganelles consisting of long chains of sarcomeres, the fundamentalcontractile units of muscle cells. Cardiomyocytes show striationssimilar to those on skeletal muscle cells, but unlike multinucleatedskeletal cells, they contain only one nucleus. Cardiomyocytes have ahigh mitochondrial density, which allows them to produce adenosinetriphosphate (ATP) quickly, making them highly resistant to fatigue.

In some embodiments, a human cardiomyocyte cell is an immortalized humancardiomyocyte or an immortalized human cardiomyocyte cell line. In someembodiments, a human cardiomyocyte cell is an immortalized humanvascular smooth muscle cell line. In some embodiments, a humancardiomyocyte as provided herein is a human immortalized cell linederived from a post-mitotic primary cell culture. In some embodiments,the post-mitotic cell line is a cardiomyocyte cell line. In anotherembodiment, the post-mitotic cell line is a vascular smooth muscle cellline. In some embodiments, the post-mitotic cell line is a neuronal cellline. In some embodiments, the post-mitotic cell line is a skeletalmyoblast cell line.

In some embodiments, a human cardiomyocyte cell is derived fromnonproliferating primary culture. As used herein the term“nonproliferating primary cultures” encompasses cell cultures whichbecome senescent after 2-3 passages (limited passage) and post-mitoticcells in culture. Such cultures also include those cells in culture thathave exited the cell cycle and are no longer capable of undergoingmitosis (post-mitotic). As used herein, the term “primary cultures”encompasses cells in culture that have been taken for an organism andnot passaged. Primary cultures herein include, but are not limited to,cells in culture originally taken from vascular smooth muscle, skeletalmyloblasts, neuronal cells, bone cells (osteoblasts, osteocytes),chondrocytes, and normal cardiomyocytes.

In some embodiments, a cell line integrates functionally with normal ormyopathic cardiac tissue as determined by measurement of syncitialbeating of the tissue. This syncitial beating can be easily measured incell culture.

In some embodiments, human cardiomyocytes are from a human ventricularcardiomyocyte cell line. In some embodiments, a human cardiomyocytecells is from an adult human ventricular cardiomyocyte cell line. Insome embodiments, a human cardiomyocyte cell line is AC10 (ATCC Cat. No.PTA-1501). In some embodiments, the human cardiomyocyte cells can beprepared according to the method described in U.S. Pat. No. 7,223,599,which is incorporated herein by reference. Briefly, adult ventricularheart tissue can be obtained from the heart transplantation facility.The ventricular tissue is dissected and minced under a dissectionmicroscope. The tissue is transferred to a glass chamber and extensivelytrypsinized at 37° C. The enzymatically dissociated cells consisting ofa mixture of all the constituent cell types of cardiac tissue areresuspended in DMEM F-12, supplemented with 12.5% Fetal Bovine Serum(FBS) and penicillin-streptomycin and are allowed to attach for an hour.The medium containing a higher concentration of cardiomyocytes that donot attach is transferred to a fresh dish and cultured at 37° C. in 5%CO₂. The culture dishes have fibroblasts which are co-cultured with thecardiomyocytes. These fibroblasts are removed by repeated selectiveplating and by repeated complement fixation using an antibody, 1B10,(Sigma Chemical Co.) to the surface protein of fibroblasts (Singer etal. (1989) J. Invest. Dermatol. 92:166-170). This resulted in cultureswith a high percentage of cardiomyocytes. If the primary cultures stopdividing, an indirect method can be used to transfer a SV-40 gene inorder to immortalize the cardiomyocytes. The surviving hybrid cells areplated at low density and subcloned with glass cloning rings(establishing a clone/colony). The clones are grown under selection, andscreened for specific cell-type markers by immunocytochemical andmolecular genetic analyses to obtain a human cardiomyocyte cell line.

5.2.4. Generation of Recombinant hERG Expressing Cardiomyocytes andCardiomyocyte Cell Lines

In some embodiments, transfer of a hERG gene (e.g., a nucleic acidsequence encoding hERG) into cells can be performed by using a vector asprovided herein. In some embodiments, the hERG gene transfer into cellscan be performed, for example, by using a viral vector as providedherein.

Gene transfer can be achieved by culturing a host cell, adding apseudovirus particle to the culture, and culturing further. In someembodiments, a pseudo-lentivirus particle is used. In some embodiments,polybrene (Sigma H9268, also known as hexadimethrine bromide) can beadded to a pseudovirus particle to be added to the culture. Twenty-fourhours after the addition of the pseudovirus particle, it is preferableto exchange the medium. It is possible to make the expression level percell highest by culturing the cell for about 72 hours after the mediumexchange. Other methods known in the art for gene transfer are includedin the present disclosure.

In some embodiments, transfer of a hERG gene (e.g., a nucleic acidsequence encoding hERG) into host cells can be performed using methodsas described in Example 2. For example, a cell line expressing hERG canbe constructed by transducing adult human ventricular cardiomyocytescell line with a pseudovirus containing an expression vector thatexpresses hERG. The expression vector can also contain a reporter geneand confer resistance for positive selection and maintenance. Theexpression vector can also contain a tag, including a FLAG tag. In someembodiments, transfer of a hERG gene into host cells can be performed bytransfection.

In some embodiments, the recombinant cardiomyocytes or cardiomyocytecell lines as provided herein comprises percentages of hERG-expressingcells. In some embodiments, more than 5% of the recombinantcardiomyocytes in the cardiomyocyte cell line express hERG. In someembodiments, more than 10% of the recombinant cardiomyocytes in thecardiomyocyte cell line express hERG. In some embodiments, more than 20%of the recombinant cardiomyocytes in the cardiomyocyte cell line expresshERG. In some embodiments, more than 30% of the recombinantcardiomyocytes in the cardiomyocyte cell line express hERG. In someembodiments, more than 40% of the recombinant cardiomyocytes in thecardiomyocyte cell line express hERG. In some embodiments, more than 50%of the recombinant cardiomyocytes in the cardiomyocyte cell line expresshERG. In some embodiments, more than 60% of the recombinantcardiomyocytes in the cardiomyocyte cell line express hERG. In someembodiments, more than 70% of the recombinant cardiomyocytes in thecardiomyocyte cell line express hERG. In some embodiments, more than 80%of the recombinant cardiomyocytes in the cardiomyocyte cell line expresshERG. In some embodiments, more than 90% of the recombinantcardiomyocytes in the cardiomyocyte cell line express hERG. In someembodiments, more than 95% of the recombinant cardiomyocytes in thecardiomyocyte cell line express hERG.

In some embodiments, the level of hERG expressed in the recombinantcardiomyocytes as provided herein is 5% to 100% more than level of hERGnaturally expressed in a cardiomyocyte. In some embodiments, the levelof hERG expressed in the recombinant cardiomyocytes as provided hereinis 10% to 100% more than level of hERG naturally expressed in acardiomyocyte. In some embodiments, the level of hERG expressed in therecombinant cardiomyocytes as provided herein is 2-fold to 100-fold ofthe level of hERG naturally expressed in a cardiomyocyte. Exemplarylevel of hERG expressed in the recombinant cardiomyocytes as providedherein is 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, more thanlevel of hERG naturally expressed in a cardiomyocyte, or about 2-fold,3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold,15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold,90-fold, or 100-fold of the level of hERG naturally expressed in acardiomyocyte. In some embodiments, the level of hERG naturallyexpressed in the cardiomyocytes is determined by measuring the level ofhERG in the cardiomyocytes prior to the transduction of the viralvector, or prior to the expression of the hERG in the cardiomyocytes viathe viral vector.

Recombinant cardiomyocytes and recombinant cell lines overexpressinghERG as provided herein also encompass those cells or cell strainsobtained by cell cloning (e.g., subcloning). Further, recombinantcardiomyocytes and recombinant cell lines overexpressing hERG asprovided herein also encompass those cells or cell lines that areobtained by transferring an hERG gene again into the cell strainobtained by the cloning.

In some embodiments, recombinant cardiomyocytes and recombinant celllines overexpressing hERG as provided herein can be subjected to cloningin order to avoid bias in nature during culture and to enable stableevaluation of drugs. Cell cloning can be performed according toconventional methods (e.g., limiting dilution culture method or cellsorting by flow cytometry).

hERG expression levels in the recombinant cardiomyocytes and recombinantcell lines overexpressing hERG as provided herein can be determined byimmunohistological analysis methods using anti-hERG antibody. Theantibodies can be prepared according to conventional methods.Alternatively, a commercial antibody (such as prepared by Alomene Labs)may be used. Exemplary immunohistological analysis methods includeenzyme immunoassay (EIA), radioimmunoassay (RIA), ELISA, Westernblotting, flow cytometry, and immunohistochemical staining.

5.2.5 Uses of hERG Expressing Cardiomyocytes and Cardiomyocyte CellLines

As shown in the Examples below, recombinant human cardiomyocytes andrecombinant cardiomyocyte cell lines overexpressing hERG as providedherein is capable of exhibiting high current with no or minor rundowneffect over a relative long time period at 37° C. or room temperature.The advantageous characteristics of such a cell line render it suitablefor a range of applications.

In some embodiments, the recombinant human cardiomyocytes overexpressinghERG expressing hERG as provided herein have a peak hERG current asdetermined by patch clamping with a fully automated high throughputpatch clamp system of 7000 pA to 3500 pA. In some embodiments, therecombinant human cardiomyocytes overexpressing hERG as provided hereinhave a peak hERG current as determined by patch clamping with a fullyautomated high throughput patch clamp system of 6500 pA or more. In someembodiments, the recombinant human cardiomyocytes overexpressing hERG asprovided herein have a peak hERG current as determined by patch clampingwith a fully automated high throughput patch clamp system of 6000 pA ormore. In some embodiments, the recombinant human cardiomyocytesoverexpressing hERG as provided herein have a peak hERG current asdetermined by patch clamping with a fully automated high throughputpatch clamp system of 5500 pA or more. In some embodiments, therecombinant human cardiomyocytes overexpressing hERG as provided hereinhave a peak hERG current as determined by patch clamping with a fullyautomated high throughput patch clamp system of 5000 pA or more. In someembodiments, the recombinant human cardiomyocytes overexpressing hERG asprovided herein have a peak hERG current as determined by patch clampingwith a fully automated high throughput patch clamp system of 4500 pA ormore. In some embodiments, the recombinant human cardiomyocytesoverexpressing hERG as provided herein have a peak hERG current asdetermined by patch clamping with a fully automated high throughputpatch clamp system of 4000 pA or more.

In some embodiments, the recombinant human cardiomyocytes overexpressinghERG as provided herein have an average hERG current as determined bypatch clamping with a fully automated high throughput patch clamp systemof 6500 pA to 2500 pA. In some embodiments, the recombinant humancardiomyocytes overexpressing hERG as provided herein have an averagehERG current as determined by patch clamping with a fully automated highthroughput patch clamp system of 6500 pA or more. In some embodiments,the recombinant human cardiomyocytes overexpressing hERG as providedherein have an average hERG current as determined by patch clamping witha fully automated high throughput patch clamp system of 6000 pA or more.In some embodiments, the recombinant human cardiomyocytes overexpressinghERG as provided herein have an average hERG current as determined bypatch clamping with a fully automated high throughput patch clamp systemof 5500 pA or more. In some embodiments, the recombinant humancardiomyocytes overexpressing hERG as provided herein have an averagehERG current as determined by patch clamping with a fully automated highthroughput patch clamp system of 5000 pA or more. In some embodiments,the recombinant human cardiomyocytes overexpressing hERG as providedherein have an average hERG current as determined by patch clamping witha fully automated high throughput patch clamp system of 4500 pA or more.In some embodiments, the recombinant human cardiomyocytes overexpressinghERG as provided herein have an average hERG current as determined bypatch clamping with a fully automated high throughput patch clamp systemof 4000 pA or more. In some embodiments, the recombinant humancardiomyocytes overexpressing hERG as provided herein have an averagehERG current as determined by patch clamping with a fully automated highthroughput patch clamp system of 3500 pA or more. In some embodiments,the recombinant human cardiomyocytes overexpressing hERG as providedherein have an average hERG current as determined by patch clamping witha fully automated high throughput patch clamp system of 3000 pA or more.In some embodiments, the recombinant human cardiomyocytes overexpressinghERG as provided herein have an average hERG current as determined bypatch clamping with a fully automated high throughput patch clamp systemof 2500 pA or more.

In some embodiments, the recombinant human cardiomyocytes overexpressinghERG as provided herein are capable of exhibiting a current that variesby less than about 50%, or alternatively, 45%, or alternatively, 40%, oralternatively, 35%, or alternatively, 30%, or alternatively, 25%, oralternatively, 20%, or alternatively, 15%, or alternatively, 10%, ofpeak current amplitude over 30 minutes as determined by patch clampingwith a fully automated high throughput patch clamp system.

In some embodiments, the recombinant human cardiomyocytes overexpressinghERG as provided herein are capable of exhibiting a current that variesby less than about 50% or alternatively, 45%, or alternatively, 40%, oralternatively, 35%, or alternatively, 30%, or alternatively, 25%, oralternatively, 20%, or alternatively, 15%, or alternatively, 10%, ofpeak current amplitude over 60 minutes as determined by patch clampingwith a fully automated high throughput patch clamp system.

In some embodiments, the current for a compound is measured during thewindow of about 450-1500 seconds by patch clamping with a fullyautomated high throughput patch clamp system. In some embodiments, therecombinant human cardiomyocytes overexpressing hERG as provided hereinare capable of exhibiting a current that varies by less than about 50%or alternatively, 45%, or alternatively, 40%, or alternatively, 35%, oralternatively, 30%, or alternatively, 25%, or alternatively, 20%, oralternatively, 15%, or alternatively, 10%, of peak current amplitudeduring 450-1500 seconds {MH}.

Recombinant human cardiomyocytes and recombinant cardiomyocyte celllines overexpressing hERG as provided herein can be used in a range ofapplications. Among these applications, of particular value toresearchers and drug developers are methods by which a candidatepharmaceutical can be tested for its effect on hERG activity. Since hERGactivity is related to long QT (LQT) syndrome, methods as providedherein can assist in the identification of compounds that are likely togive rise to a LQT condition. This ability can minimize the risk to apatient of LQT-related injury. Methods as provided herein can,therefore, be employed in drug design.

Thus, provided herein is a method of measuring hERG current inhibitoryactivity comprising using the cells or cell lines as provided herein.Also provided herein is a method of screening a compound or a saltthereof for its hERG current altering effect comprising using the cellsor cell lines as provided herein.

The following discussion is not meant to be an all-encompassingdescription of the methods as provided herein. Additionally, althoughthe steps of various methods are disclosed in the context of one singlemethod, it is understood that the general discussion accompanying themethods is intended to apply to disclosed methods. Variations on thedisclosed methods can be made fall within the claims and spirit of thepresent disclosure. Such variations on the disclosed methods will beapparent to those of skill in the art upon contemplation of the presentdisclosure.

5.2.5.1. Methods for Drug Screening and/or Drug Development

Recombinant human cardiomyocytes and recombinant cardiomyocyte celllines overexpressing hERG as provided herein can be used in drugscreening and development, including for drug-associated cardiotoxicity(e.g., hERG-related cardiotoxicity) that is related to inhibition of(e.g., by blocking or obstructing, either fully or partially) hERGand/or for drug-associated cardiotoxicity (e.g., non-hERG-relatedcardiotoxicity) that is not specifically related to inhibition of (e.g.,by blocking or obstructing, either fully or partially) hERG, asdisclosed herein. For any and all of the following methods, thecompounds can include novel or previously known drugs.

The methods as provided herein can also be employed to identify the riskof drugs to give rise to arrhythmias, e.g., long QT syndrome (LQT), asmeasured by inhibition of (e.g., by blocking or obstructing, eitherfully or partially) hERG. In some embodiments, the methods as providedherein are applied to a candidate pharmaceutical that is in developmentto assist a drug designer or researcher to identify a candidatepharmaceutical that is likely to give rise to arrhythmias and, ifdesired, to remove the candidate from the research program, or providesuitable warning to medical practitioners and patients based on dataderived from the methods as provided herein.

In some embodiments, the methods as provided herein can be used toidentify or screen drugs for their risk of giving rise to LQT. One formof LQT is an inherited cardiac arrhythmia that causes abrupt loss ofconsciousness, syncope, seizures and sudden death from ventriculartachyarrhythmias, specifically torsade de pointes and ventricularfibrillation (Ward (1964) J. Ir. Med. Assoc. 54, 103-106; Romano (1965)Lancet 1658-659; Schwartz et al. (1975) Am. Heart J. 109: 378-390; Mosset al. (1991) Circulation 84: 1136-1144.). This disorder usually occursin young, otherwise healthy individuals (Ward (1964) J. Ir. Med. Assoc.54: 103-106; Romano (1965) Lancet 1658-659; Schwartz et al. (1975) Am.Heart J. 109: 378-390). Most LQT gene carriers manifest prolongation ofthe QT interval on electrocardiograms, a sign of abnormal cardiacrepolarization (Vincent et al. (1992) N. Engl. J. Med. 327: 846-852).

In some embodiments, the methods as provided herein can be applicable todrugs already in the marketplace to identify drugs that can pose a riskof arrhythmias, e.g., LQT, and can be marked as such.

In some embodiments, the methods as provided herein can be used forscreening or selecting compounds from the collections of a chemical orcompound library, for example, new drug candidates generated by organicor medicinal chemists as part of a drug discovery and/or drugdevelopment program.

In some embodiments, the methods as provided herein can be used todesign compounds or drugs with reduced cardiotoxicity or reduced risk toa patient.

5.2.5.2. Methods of Identifying Candidate Compounds as hERG ChannelInhibitors

Recombinant human cardiomyocytes and recombinant cardiomyocyte celllines overexpressing hERG as provided herein can be used in drugscreening and development, including for drug-associated cardiotoxicitythat is related to inhibition of (e.g., by blocking or obstructing,either fully or partially) hERG. For any and all of the followingmethods, the compounds can include novel or previously known drugs.

In some embodiments, provided herein are methods of identifyingcandidate compounds as hERG inhibitors. For example, many therapeuticsare hERG inhibitors. While some of these therapeutics were designed ashERG channel inhibitors, others exhibit hERG channel inhibition as anundesired side effect. The cells or cell lines as provided herein can beused to identify a candidate compound as a hERG channel inhibitor.

In some embodiments, the methods as provided herein comprise providingthe recombinant human cardiomyocytes and recombinant cardiomyocyte celllines overexpressing hERG of the present disclosure. A candidatecompound can then be contacted with the cells or cell lines. In someembodiments, the contacting can be performed by dripping a solutioncomprising the candidate compound over the cell(s). For example, thecontacting can be performed in a sterile environment and/or anenvironment in which conditions are controlled and maintained at levelswhich preserve the integrity of the cell(s). Various methods ofcontacting can be employed according to the present methods and will beapparent to those of skill in the art upon consideration of the presentdisclosure. A hERG activity is then determined in the presence of thecandidate compound. The method of the determination can be dictated, inpart, by the nature of the biological activity. In some embodiments, thebiological activity is transport of potassium ions, and transport ofpotassium ions can be detected via detection of a voltage or current,which can accompany transport of potassium ions. Such a current can bedetected, and this biological activity determined by employing a patchclamp apparatus, such as the patch clamp apparatus disclosed herein.

In some embodiments, the biological activity of the hERG potassiumchannel determined in the presence of the candidate compound can becompared with hERG potassium channel activity determined in an absenceof the candidate compound. In some embodiments, the comparison is aquantitative comparison, and can optionally involve a statisticalanalysis. In some embodiments, the candidate compound can be identifiedas a hERG channel inhibitor if the biological activity of the hERGpotassium channel in the presence of the candidate compound is lowerthan the biological activity of the hERG potassium channel in theabsence of the candidate compound. In some embodiments, hERG currentinhibitory activities can be determined by using as an indicator theratio of the amplitude of hERG current after contacting a compound tothe amplitude of hERG current before contacting the compound.

In some embodiments, an extracellular ion concentration or anotherintervention (such as an applied electric field, or a compound thatalters the membrane potential) can be manipulated to set a membranepotential at a level that will likely change when a compound binds tothe target hERG channel.

For example, stably-transduced human cardiomyocyte cells can be grown inculture plates and then loaded with a voltage-sensitive dye (e.g.,carbocyanides, DiANEPP, diBAC, etc.) with a dynamic range and responsetime that allows detection of transmembrane voltage. A compound ofinterest can then be applied to each well of the dish, with theappropriate control also being applied. Transmembrane potential can thenbe recorded using any of a variety of detection methods, such asautomated fluorescence detection for multiple samples (e.g., FLIPRtechnology). By assessing the effects of varying concentrations ofcompounds in cells that express hERG, the effect of the compound on hERGbiological activity can be assessed.

In some embodiments, when a biological activity is potassium iontransport, the determining can be performed by measuring a voltage orcurrent across the structure. In some embodiments, such measurements areperformed by employing patch clamp technology, which is also describedelsewhere herein. In some embodiments, patch-clamp experiments can beperformed at 37° C. In some embodiments, patch-clamp experiments can beperformed at room temperature (21-23° C.).

In some embodiments, for example, the amplitude of the hERG currentbefore the contact with the compound is taken as 100% and 0 nA is takenas 0%. Then, inhibition ratio is calculated from the amplitude of thehERG current after the contact with the compound, followed bydetermination of the hERG current inhibitory activity of the compound.Further, it is also possible to calculate the inhibitory activity valueinherent in the test compound by varying the dose of the compound. Insome embodiments, when the concentration of the compound inducing 50%inhibition of hERG currents is at least 0.3 μM or more, the compound canbe judged as not affecting hERG currents or not having inhibitoryactivity. In some embodiments, when the concentration of the compoundinducing 50% inhibition of hERG currents is at least 1.0 μM or more, thecompound can be judged as not affecting hERG currents or not havinginhibitory activity. In some embodiments, when the concentration of thecompound inducing 50% inhibition of hERG currents is at least 3.0 μM ormore, the compound can be judged as not affecting hERG currents or nothaving inhibitory activity. In some embodiments, when the concentrationof the compound inducing 50% inhibition of hERG currents is at least10.0 μM or more, the compound can be judged as not affecting hERGcurrents or not having inhibitory activity. In some embodiments, whenthe concentration of the compound inducing 50% inhibition of hERGcurrents is at least 30.0 μM or more, the compound can be judged as notaffecting hERG currents or not having inhibitory activity.

“IC₅₀” or “IC₉₀” may be used in some embodiments to determine theinhibitory effect of the compound. As used herein, the terms “IC₅₀” and“IC₉₀” refer to the concentration of a compound that reduces (e.g.,inhibits) the activity of a target by 50% and 90%, respectively. Theterm “IC₅₀” generally describes the inhibitory concentration of thecompound. Typically, measurements of IC₅₀ and IC₉₀ are made in vitro. Insome embodiments, where the target is a secondary biological target, forexample, a membrane-bound ion channel implicated in cardiac cytotoxicity(e.g., hERG), IC₅₀ is the concentration at which 50% inhibition isobserved. IC₅₀'s and IC₉₀'s can be measured according to any methodknown to one of ordinary skill in the art.

It is known that compounds with hERG current inhibitory activity havearrhythmogenesis effect accompanied by QT interval prolongation effect.Such compounds may induce serious adverse effects such as ventriculartachycardia or sudden death. Therefore, in the development of highlysafe pharmaceuticals, it is important to confirm that the test substance(target of development) does not affect hERG currents. The method ofmeasuring hERG current inhibitory activities using the hERG-expressinghuman cardiomyocyte cell as provided herein facilitates the selection ofcompounds that do not affect hERG currents. Therefore, recombinant humancardiomyocytes and recombinant cardiomyocyte cell lines overexpressinghERG as provided herein can be used to predict the risk of a candidatedrug to induce cardiac arrhythmia, and is useful in developingpharmaceuticals such as therapeutics and prophylactics for variousdiseases. In some embodiments, the methods as provided herein can beused by a drug designer to identify a candidate drug that poses a riskto a patient of cardiac arryhmia, which can lead to injury or death.

In some embodiments, the methods as provided herein include providingrecombinant human cardiomyocytes and recombinant cardiomyocyte celllines overexpressing hERG of the present disclosure. A compound (e.g.,candidate drug) can then be contacted with the cells or cell lines. Thecontacting can be achieved in any convenient and feasible way. Forexample, a candidate drug can be suspended in a solution and thesolution can be dripped onto the cells or cell lines. Alternatively, thecells can be placed in a bathing solution or medium and a candidate drugcan be added to the bathing solution or the medium. Then, hERGinhibitory activity in the presence of a candidate drug is determined.This determination can be made by employing the techniques disclosedherein. For example, biological activity of potassium ion transport canbe determined by patch clamp or ion flux. The hERG inhibitory activityin an absence of a candidate drug is compared to hERG inhibitoryactivity in the presence of the candidate drug. In some embodiments,hERG inhibitory activity in the absence of a candidate drug can bedetermined by employing the same techniques that were employed todetermine the biological activity in the presence of the candidate drug(e.g., patch clamp or ion flux techniques). In some embodiments, thisdetermination can be made just prior to the determination of activity inthe presence of a candidate drug. In some embodiments, the activity of achannel in the absence of a candidate drug can also be determined wellahead of time or can comprise a standard reference activity, eliminatingthe need for performing the assay.

In some embodiments, the analysis of the comparison can provide data onthe risk of a candidate drug to induce cardiac arrhythmia. For example,if hERG inhibitory activity in the presence of a candidate drug isgreater than hERG inhibitory activity in an absence of the candidatedrug, it is indicative of a risk of the drug to induce cardiacarrhythmia in a subject.

5.2.5.2.1 Patch Clamp Techniques

Various assays and techniques known in the art can be used forpracticing the methods as provided herein. The assays described hereinare meant to be representative, those of skill in the art, uponconsideration of the present disclosure, will recognize additionalassays and techniques that are useful in performing the present methods.In some embodiments, the assays are in vitro biological assays fortesting hERG1 channel activity, for example, a FluxOR™ potassium ionchannel assay, or electrophysiology measurements in single cells, asexplained below.

In some embodiments, the methods as provided herein comprise monitoringion flow through a pore using patch clamp, or voltage clamp. The clamptechnique and improvements thereof, have been developed to studyelectrical currents in cells, and to study ion transfer throughchannels. To measure these currents, the membrane of a cell is closelyattached to the opening of the patch micropipette so that a very tightseal is achieved. This seal prevents current from leaking outside of thepatch micropipette. The resulting high electrical resistance across theseal can be exploited to perform high resolution current measurementsand apply voltages across the membrane. Different configurations of thepatch clamp technique can be employed. (Sakmann & Neker, (1984) Ann.Rev. Physiol. 46: 455).

Thus, in some embodiments, the present disclosure provides methods ofmeasuring hERG currents using a hERG-expressing cell or hERG-expressingcell population as provided herein by the patch clamp technique. In someembodiments, provided herein are methods of measuring hERG currentsusing the recombinant human cardiomyocytes overexpressing hERG asprovided herein by a fully automated high throughput patch clamp system.

Recombinant human cardiomyocytes overexpressing hERG can be obtained bythe above-described methods. In some embodiments, the channel current asdetermined by patch clamping with a fully automated high throughputpatch clamp system for hERG-expressing cell as provided herein is 3500pA or more. In some embodiments, the channel current as determined bypatch clamping with a fully automated high throughput patch clamp systemfor hERG-expressing cell as provided herein is 4000 pA or more. In someembodiments, the channel current as determined by patch clamping with afully automated high throughput patch clamp system for hERG-expressingcell as provided herein is 4500 pA or more. In some embodiments, thechannel current as determined by patch clamping with a fully automatedhigh throughput patch clamp system for a hERG-expressing cell asprovided herein is 5000 pA or more. In some embodiments, the channelcurrent as determined by patch clamping with a fully automated highthroughput patch clamp system for the hERG-expressing cell as providedherein is 6000 pA or more. Such a hERG-expressing cells orhERG-expressing cell lines is also included in the scope of the presentdisclosure. It should be noted here that the higher the expression levelis, the higher the channel current as determined by patch clamptechnique becomes.

In some embodiments for practicing methods of measuring hERG currents asprovided herein, a recombinant cardiomyocytes cells overexpressing hERGas provided herein can be cultured for a specific period of time andsuspended in a buffer suitable for measurement. Any buffer which doesnot affect hERG currents can be used, e.g., phosphate buffer or Tris-HClbuffer at pH 6-8. In some embodiments, phosphate buffered saline (pH7.4) is used.

Subsequently, hERG currents can be recorded by a patch clamp technique,e.g., with a fully automated high throughput patch clamp system. hERGcurrents can be induced by giving various holding potentials anddepolarizing pulses to cells. These conditions can be set by thoseskilled in the art (Zhou et al. (1998) Biophysical Journal, 74,230-241). For example, hERG currents can be induced by changing theholding potential from −80 mV to +20 mV for 1 sec and then applying adepolarizing pulse to −50 mV for 1 sec. The peak value of the tailcurrent can be used when the potential is restored to −50 mV. In someembodiments, the voltage command can be set as described in Example 4 orExample 5.

In some embodiments, a cell without a compound and the cell with acompound which is known to inhibit hERG currents can be prepared ascontrols. Specific examples of compounds that inhibit hERG currentsinclude astemizole (Talialatel et al. (1998) Mol. Pharmacol. 54:113-21), E-4031 (Zhou et al. (1998) Biophys. J. 74: 230-41; Kim et al.(2005) J. Appl. Physiol. 98(4): 1469-1477), risperidone (Kongsamut etal. (2002) Eur. J. Pharmacol. 450: 37-41), verapanil (Zhang et al.(1999) Circ. Res. 84: 989-98) and quinidine (Jiesheng et al. (2001) J.Pharmacol. Exp. Ther. 299: 290-6).

In some embodiments, an in vitro biological assay comprises patch clampelectrophysiology measurements, which use a high throughput single cellplanar patch clamp approach (see, e.g., Schroeder et al. (2003) J.Biomol. Screen. 8(1): 50-64). In some embodiments, single cells are froma human adult cardiomyocyte cell line expressing hERG as providedherein. For example, human cardiomyocyte cells are dispensed into apatch plate. Amphotericin is used as a perforating agent to gainelectrical access to the cells. The hERG tail current is measured priorto the addition of a compound by perforated patch clamping. Followingaddition of the compound, a second recording of the hERG current isperformed. Post-compound hERG currents are usually expressed as apercentage of pre-compound hERG currents (% control current) and plottedagainst concentration for each compound. Where concentration dependentinhibition is observed, the Hill equation is used to fit a sigmoidalline to the data and an IC₅₀ (concentration at which 50% inhibition isobserved) is determined.

5.2.5.2.2 Ion Flux Assay

A compound can be tested for its ability to modulate a potassium channelby determining the influx of ion tracers through the channel.Representative labeled potassium ions that can be employed to assaychannel conductance include but are not limited to ⁴¹K. In someembodiments, aliquots of a cell suspension comprising recombinant humancardiomyocytes overexpressing hERG are incubated for 10 minutes at 37°C. in the presence of channel openers and test substances in a totalvolume of 100 μM (0.20-0.25 mg protein). Ion flux is initiated by theaddition of HEPES/TRIS solution also containing 4 mM guanidine HCl(final) and 1000 dpm/nmol ¹⁴C guanidine. The reaction can be continuedfor 30 seconds and be stopped by the addition of ice-cold incubationbuffer, followed by rapid filtration under vacuum over a glassmicrofiber filter (grade GF/C, 1.2 μm available from Whatman, Inc. ofClifton, N.J.). The filters are washed rapidly with ice-cold incubationbuffer and radioactivity is determined by scintillation counting.Nonspecific uptake can be determined in parallel reactions.

In some embodiments, an ion flux assay can further comprise contacting ahuman cardiomyocytes cells expressing hERG with a test substance. Forexample, substantial ion flux can be observed in the presence of a hERGchannel activator, and a reduction of flux following subsequentapplication of a test substance indicates an antagonist activity of thetest substance. Similarly, observation of enhanced ion flux of analready-activated hERG channel following application of a test substanceindicates an agonist activity of the test substance.

In some embodiments, an in vitro biological assay as provided herein isa FluxOR™ potassium ion channel assay (see, e.g., Beacham et al. (2010)J. Biomol. Screen. 15(4): 441-446), which allows high throughputscreening of potassium ion channel and transporter activities. TheFluxOR™ assay monitors the permeability of potassium channels tothallium (Tl⁺) ions. When thallium is added to the extracellularsolution with a stimulus to open channels, thallium flows down itsconcentration gradient into the cells, and channel or transporteractivity is detected with a proprietary indicator dye that increases incytosolic fluorescence. Accordingly, fluorescence reported in theFluxOR™ system is an indicator of any ion channel activity or transportprocess that allows thallium into cells.

5.2.5.2.3 Membrane Potential Assay Kit

In some embodiments, methods as provided herein comprise measuringchanges in membrane potential on the hERG-expressing human cardiomyocytecell using FLIPR Membrane Potential Assay Kit (Molecular Devices). Forexample, changes in membrane potential can be measured by performing thefollowing operations. hERG-expressing cells or cell lines can beprepared according to methods as provided herein in order to prepare acell suspension of a concentration of 0.2×10⁵ cells/ml to 1.0×10⁶cells/ml. Subsequently, the cell suspension is plated on plates (such asBiocoat Poly-D-Lysine 384-Well Black/Clear Plate; BECKTON DICKINSON) andcultured further. Subsequently, Component A contained in FLIPR MembranePotential Assay Kit (Molecular Devices) is dissolved in a measurementbuffer (130 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂, 24 mM Glucose, 10mM HEPES (final pH: approx. 7.25)), and a 25 μl aliquot of this solutionis added to each well. About one hour after the addition of Component A,changes in membrane potential can be measured with FLIPR (MolecularDevices) or FDSS6000 (Hamamatsu Photonics).

5.2.5.3. Methods of Identifying Candidate Compounds for Reduction inCell Viability

Cardiomyocytes and cardiomyocyte cell lines as provided herein can beused in drug screening and development, including for drug-associatedcardiotoxicity that is related to reduction in cell viability. For anyand all of the following methods, the compounds can include novel orpreviously known drugs.

Assays for cell viability include assays that measure metaboliccapacity, proliferation, apoptosis, mitochondrial damage, and/or plasmamembrane damage using a variety of assays known in the art (e.g., anATP/ADP assay; a Calcein AM assay; a clonogenic assay; an ethidiumhomodimer assay; a cytochrome oxidase activity assay; an adenylatekinase (AK) assay; an Alamar Dye/Setublue assay; a lactate dehydrogenase(LDH) assay; formazan-based assays (MTT/XTT); reduction of MTStetrazolium; dyes such as, e.g., Evans blue, neutral red, methyl violet,propidium iodide, sulforhodamine B, fluorescein diacetatehydrolysis/Propidium iodide staining (FDA/PI staining),carboxyfluorosuccinimide ester (CFSE) dye, Resazurin, Trypan Blue, and aliving-cell exclusion dye (dye only crosses cell membranes of deadcells)); detection of mutations in mtDNA; release of components acrossthe mitochondrial permeability transition pore; changes in mitochondrialmembrane potential; flow cytometry; green fluorescent protein; a DNAstain that can differentiate necrotic, apoptotic and normal cells;measurement of cytochrome c release; caspase proteolytic cleavage ofpoly(ADP-ribose) polymerase (PARP); detection of Annexin V;senescence-associated expression of β-galactosidase (SA-β-Gal) activity;a TUNEL assay; and the like). Also see, e.g., “Mammalian CellViability—Methods and Protocols,” Methods in Molecular Biology, April2011, edited by Stoddart, Martin J. In such assays, a candidate drug canbe contacted with the cells or cell lines. The contacting can beachieved in any convenient and feasible way. For example, a candidatedrug can be suspended in a solution and the solution can be dripped ontothe cells or cell lines. Alternatively, the cells can be placed in abathing solution or medium and a candidate drug can be added to thebathing solution or the medium. Viability of the cell(s) in the presenceof a candidate drug is determined. In some embodiments, viability isdetermined by employing a cell proliferation assay, for example, acolorimetric or a fluorescence cell proliferation assay as describedherein.

In some embodiments, the analysis of the comparison can provide data onthe risk of cardiotoxicity of a candidate drug. For example, if theviability of the cell(s) in the presence of a candidate drug is lessthan the viability of the cell(s) in an absence of the candidate drug,it is indicative of a risk of the drug to be cardiotoxic in a subject.

5.2.5.3.1 Fluorescence Cell Viability Assay

A compound can be tested for its ability to reduce cell viability, asmeasured in a fluorometric proliferation assay (e.g., SetuBlue™ CellProliferation Assay Kit (Fluorometric)) employing the techniquesdisclosed herein. The viability of the cell(s) in an absence of acompound is compared to the viability of the cell(s) in the presence ofthe compound.

5.2.5.3.2 Luminescence Cell Viability Assay

A compound can be tested for its ability to reduce cell viability, asmeasured in a luminescence assay (e.g., CellTiter-Glo®, RealTime-Glo™,CelITox™ Green, TACS® MTT Cell Proliferation Assay, TACS® XTT CellProliferation Assay). The viability of the cell(s) in an absence of acompound is compared to the viability of the cell(s) in the presence ofthe compound.

5.2.5.4. Methods of Predicting Risks of Candidate Compounds to CauseCardiotoxicity

It is further known that compounds with hERG current inhibitor activityas well as compounds with weak or absent hERG current inhibitoryactivity may be cardiotoxic. Therefore, in the development of highlysafe pharmaceuticals, it is important to evaluate the test substance(target of development) for cardiotoxicity in assays to determine hERGcurrent inhibitory activity and/or in assays to determine cell viabilityinhibitory activity. Cardiomyocytes and cardiomyocyte cell lines, asprovided herein, are useful in both assays of hERG current inhibitoryactivity and cell viability inhibitory activity. In some embodiments,cardiotoxicity of candidate compounds is not caused by inhibition of(e.g., by blocking or obstructing, either fully or partially) hERG.Methods that allow evaluation of cell viability, when combined withmethods that allow determination of inhibition of the hERG channel, canidentify compounds that are: (i) hERG inhibitors, but not inhibitors ofcell viability; (ii) hERG inhibitors and inhibitors of cell viability;(iii) inhibitors of cell viability, but not inhibitors of hERG; and (iv)not inhibitors of hERG and not inhibitors of cell viability.Cardiomyocytes and cardiomyocyte cell lines, as provided herein, arealso useful in understanding mechanisms of toxicity of compounds asrevealed by ultrastructural changes in the cells and cell lines treatedwith the compounds, for example, changes in cytoskeleton, nucleus,mitochondria, golgi, and/or other sub-cellular compartments.

The methods of determining cardiotoxicity using the hERG-expressinghuman cardiomyocyte cardiomyocytes and cardiomyocyte cell lines asprovided herein facilitate the selection of compounds that are notcardiotoxic. Therefore, cells or cell lines as provided herein can beused to predict the risk of cardiotoxicity of a candidate drug, and areuseful in developing pharmaceuticals such as therapeutics andprophylactics for various diseases. In some embodiments, the methods asprovided herein can be used by a drug designer or developer to identifya candidate drug that poses a risk to a patient of cardiotoxicity, whichcan lead to injury or death.

5.2.5.5. Compounds

Examples of compounds include peptides, proteins, non-peptidiccompounds, synthetic compounds, fermentation products, cell extracts,plant extracts and animal tissue extract. The compounds can be eithernovel compounds or known compounds.

In some embodiments, the compound is selected from a list of compoundsthat have failed in clinical trials, or were halted in clinical trialsdue to cardiotoxicity.

In some embodiments, the compound is selected from TABLE A, below:

TABLE A Cardiac Hazardous Drugs Category of Drug Drug Calcium channelPrenylamine (TdP reported; withdrawn) blockers Bepridil (TdP reported;withdrawn) Terodiline (TdP reported; withdrawn) Psychiatric drugsThioridazine (TdP reported) Chlorpromazine (TdP reported) Haloperidol(TdP reported) Droperidol (TdP reported) Amitriptyline NortriptylineImipramine (TdP reported) Desipramine (TdP reported) ClomapramineMaprotiline (TdP reported) Doxepin (TdP reported) Lithium (TdP reported)Chloral hydrate Sertindole (TdP reported; withdrawn in the UK) Pimozide(TdP reported) Ziprasidone Antihistamines Terfenadine (TdP reported;withdrawn in the USA) Astemizole (TdP reported) Diphenhydramine (TdPreported) Hydroxyzine Ebastine Loratadine Mizolastine Antimicrobial andErythromycin (TdP reported) antimalarial drugs Clarithromycin (TdPreported) Ketoconazole Pentamidine (TdP reported) Quinine Chloroquine(TdP reported) Halofantrine (TdP reported) Amantadine (TdP reported)Sparfloxacin Grepafloxacin (TdP reported; withdrawn) Pentavalentantimonial meglumine Serotonin agonists/ Ketanserin (TdP reported)antagonists Cisapride (TdP reported; withdrawn) ImmunosuppressantTacrolimus (TdP reported) Anticancer agents Doxorubicin EpirubicinIdarubicin Daunorubicin Antidiuretic hormone Vasopressin (TdP reported)Other agents Adenosine Organophosphates Probucol (TdP reported)Papaverine (TdP reported) Cocaine

In some embodiments, the compound is an anticancer agent, such asanthracyclines, mitoxantrone, cyclophosphamide, fluorouracil,capecitabine and trastuzumab. In some embodiments, the compound is ananthracycline. In some embodiments, the compound is doxorubicin.

In some embodiments, the compound is an immunomodulating drug, such asinterferon-alpha-2, interleukin-2, infliximab and etanercept. In someembodiments, the compound is an antidiabetic drug, such asrosiglitazone, pioglitazone and troglitazone. In some embodiments, thecompound is an antimigraine drug, such as ergotamine and methysergide.In some embodiments, the compound is an appetite suppressant, such asfenfulramine, dexfenfluramine and phentermine. In some embodiments, thecompound is a tricyclic antidepressants. In some embodiments, thecompound is an antipsychotic drug, such as clozapine. In someembodiments, the compound is an antiparkinsonian drug, such as pergolideand cabergoline. In some embodiments, the compound is an glucocorticoid.In some embodiments, the compound is an antifungal drugs such asitraconazole and amphotericin B. In some embodiments, the compound is anNSAID, including selective cyclo-oxygenase (COX)-2 inhibitors.

In some embodiments, the compound is selected from the group consistingof an antihistamine, an antiarrhythmic, an antianginal, anantipsychotic, an anticholinergic, an antitussive, an antibiotic, anantispasmodic, a calcium antagonist, an inotrope, an ACE inhibitor, anantihypertensive, a beta-blocker, an antiepileptic, a gastroprokineticagent, an alpha1-blocker, an antidepressant, an aldosterone antagonist,an opiate, an anesthetic, an antiviral, a PDE inhibitor, an antifungal,a serotonin antagonist, an antiestrogen, and a diuretic.

In some embodiments, the compound is an active ingredient in a naturalproduct. In some embodiments, the compound is a toxin or environmentalpollutant.

In some embodiments, the compound is an antiviral agent.

In some embodiments, the compound is selected from the group consistingof a protease inhibitor, an integrase inhibitor, a chemokine inhibitor,a nucleoside or nucleotide reverse transcriptase inhibitor, anon-nucleoside reverse transcriptase inhibitor, and an entry inhibitor.

In some embodiments, the compound is capable of inhibiting hepatitis Cvirus (HCV) infection.

In some embodiments, the compound is an inhibitor of HCV NS3/4A serineprotease.

In some embodiments, the compound is an inhibitor of HCV NS5B RNAdependent RNA polymerase.

In some embodiments, the compound is an inhibitor of HCV NS5A monomerprotein.

In some embodiments, the compounds is selected from the group consistingof Abacavir, Aciclovir, Acyclovir, Adefovir, Amantadine, Amprenavir,Ampligen, Arbidol, Atazanavir, Balavir, Boceprevirertet, Cidofovir,Darunavir, Delavirdine, Didanosine. Docosanol, Edoxudine, Efavirenz,Emtricitabine, Enfuvirtide, Entecavir, Famciclovir, Fomivirsen,Fosamprenavir, Foscarnet, Fosfonet, Ganciclovir, Ibacitabine, Imunovir,Idoxuridine, Imiquimod, Indinavir, Inosine, Interferon type Ill,Interferon type II, Interferon type I, Interferon, Lamivudine,Lopinavir, Loviride, Maraviroc, Moroxydine, Methisazone, Nelfinavir,Nevirapine, Nexavir, Oseltamivir (Tamiflu), Peginterferon alfa-2a,Penciclovir, Peramivir, Pleconaril, Podophyllotoxin, Raltegravir,Ribavirin, Rimantadine, Ritonavir, Pyramidine, Saquinavir, Sofosbuvir,Stavudine, Telaprevir, Tenofovir, Tenofovir disoproxil, Tipranavir,Trifluridine, Trizivir, Tromantadine, Truvada, Valaciclovir (Valtrex),Valganciclovir, Vicriviroc, Vidarabine, Viramidine, Zalcitabine,Zanamivir (Relenza), and Zidovudine.

In some embodiments, the compound is selected from the group consistingof terfenadine, astemizole, grepafloxacin, terodiline, droperidol,lidoflazine, sertindole, levomethadyl and cisapride.

In some embodiments, the compound is selected from the group consistingof ivabradine, dofetilide, ibutilide, E-4031, MK-499, KN-93, amiodarone,cisapride, haloperidol, droperidol, bepridil, terfenadine, propafenone,domperidone, changrolin, and bertosamil. In some embodiments, thecompound is selected from the group consisting of amiodarone, cisapride,droperidol and haloperidol. In some embodiments, the compound isselected from the group consisting of bepridil, domperidone, E-4031 andterfenadine.

In some embodiments, the compound is ivabradine, for which the chemicalname is“3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one.”The structure of ivabradine is provided below:

In some embodiments, the compound is a methanesulfonanilide, forexample, dofetilide or ibutilide.

In some embodiments, the compound is dofetilide, for which the chemicalname is “N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide.”The structure of dofetilide is provided below:

In some embodiments, the compound is cisapride, for which the chemicalname is“(±)-cis-4-amino-5-chloro-N-(1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl)-2-methoxybenzamide.”The structure of cisapride is provided below:

In some embodiments, the compound is Daclatasvir (BMS-790052), for whichthe chemical name is “Methyl[(2S)-1{(2S)-2-[5-(4′-{2-[(2S)-1{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}2-pyrrolidinyl]-1H-imidazol-5-yl}4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}3-methyl-1-oxo-2-butanyl]carbamate.”The structure of Daclastavir is provided below:

In some embodiments, the compound is BMS-986094, for which the chemicalname is “(2R)-neopentyl2-(((((2R,3R,4R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)amino)propanoate.”The structure of BMS-986094 is illustrated below:

In some embodiments, the compounds are: (i) hERG inhibitors, but notinhibitors of cell viability; (ii) hERG inhibitors and inhibitors ofcell viability; (iii) inhibitors of cell viability, but not inhibitorsof hERG; and (iv) not inhibitors of hERG and not inhibitors of cellviability.

The following examples are included to demonstrate preferred embodimentsof the disclosure. It should be appreciated by those of ordinary skillin the art that the techniques disclosed in the examples which followrepresent techniques discovered by the inventor to function well in thepractice of the disclosure, and thus can be considered to constitutepreferred modes for its practice. However, those of ordinary skill inthe art should, in light of the present disclosure, appreciate that manychanges can be made in the specific embodiments which are disclosed andstill obtain a like or similar result without departing from the spiritand scope of the disclosure.

6. EXAMPLES 6.1 Example 1: Transfection of HEK-293T Cells to GeneratePseudo-Lenti Viral Particles

A hERG expression clone containing a human KCNH2 gene sequence withC-Flag tag (Uniprot Accession #Q12809; GeneCopoeia™ vectorEX-A1128-Lv203; see FIG. 4A), CMV promoter, eGFP and puromycin stableselection marker was transformed into stbl3 chemically competent E.coli. The Promega PureYield™ Plasmid Maxiprep kit (Catalog #A2392) wasused to purify the plasmid from transformed bacteria lysates. Thepurified plasmids were characterized by restriction digestion, UVabsorption spectrum and DNA sequencing.

Pseudovirus particles were generated in HEK-293T cells by transfectingusing the Lenti-Pac™ HIV Expression Packing Kit (GeneCopoeia Catalog#HPK-LvTR-20). Briefly, HEK-293T cells (ATCC Cat. No. CRL-11268) wereseeded one or two days before the transfection in a 6 well plate or a 10cm dish in complete growth media (DMEM) supplemented with 10% heatinactivated fetal bovine serum (FBS), so that the cells were 65-80%confluent at the time of transfection. The cells were incubated inhumidified incubator at 37° C. with 5% CO₂.

Transfections were carried out according to manufacturer's protocols(Genecopoeia/Promega/Invitrogen). More specifically, 2-3 μg oflentiviral ORF expression plasmid DNA and 4-6 μl of Lenti-Pac™ HIV mixwere first mixed in 200 μl Opti-MEM I in a tube. In a separate tube,12-18 μl of EndoFectin Lenti was diluted with 200 μl Opti-MEM I media.The diluted EndoFectin Lenti reagents were added drop wise to theDNA-containing tube. The mixture was incubated at room temperature for10-30 minutes to allow the DNA-EndoFectin complex to form. The complexmixture was then added directly to each well and the plate was gentlyswirled. After incubation at 37° C. and 5% CO₂ for 12-16 h, the mediumcontaining the mixtures was gently removed, and fresh growth medium wasadded. At 36, 48 and 72 hours post transfection, psedudovirus-containingculture medium was collected in sterile capped tubes, and the tubes werecentrifuged. The supernatant was filtered through 0.45 μM lowprotein-binding filters.

The viral titer was estimated by qRT-PCR using Lenti-Pac HIV qRT-PCRTitration Kit (GeneCopoeia, Catalog #HPR-LTK-050). Transductionefficiency was monitored in HEK-293T cells by analyzing eGFP expressionusing flow cytometry (FACS Calibur BD Bioscience).

6.2 Example 2: Generation of Recombinant Cardiomyocytes andCardiomyocyte Cell Lines Expressing hERG

Cells expressing hERG were prepared by transducing cells from AC10 adulthuman ventricular cardiomyocytes (ATCC Cat. No. PTA-1501) with thepseudovirus particles generated in Example 1 containing an expressionvector that expresses a C-terminal FLAG-tagged hERG. This expressionvector also contains a bicistronic eGFP reporter gene and conferspuromycin resistance for positive selection and maintenance.

More specifically, adult human ventricular cardiomyocytes (AC10 cells,ATCC catalog #PTA-1501) are referred to herein as hMYO cells and wereseeded in a 24-well plate two days before viral infection. The cellsreached to 65-80% confluency at the time of transduction. The cells werecultured in DMEM/F-12 (Gibco, Catalog #11330-032) supplemented with10-12.5% heat inactivated FBS and 100 units/ml penicillin/streptomycin,and were maintained throughout this study at 37° C. and 5% CO₂ in ahumidified chamber. Such hMYO cells are useful as control cells.

The cells were infected with diluted pseudovirus particles in presenceof low serum growth medium and 5-8 μg/ml of Polybrene (Sigma-AldrichCatalog #H9268). At 12 hours post infection, cultures were washed withPBS (HyClone catalog #SH30256.01). The cells were then cultured in freshlow serum growth medium (DMEM/F12). 2 days post-transduction, the cellswere passaged, split (1:5) by trypsinized, reseeded onto 6-well plate,and incubated for 48 hours in complete growth medium. The transientexpression of transgenes in the infected target cells was analyzed byflow cytometry or with a fluorescent microscope. The media was replacedevery 3-4 days with fresh low serum growth medium containing 20-50 μg/mlof selection drug (Puromycin) until drug resistance colonies becomevisible to select stably transduced cells. The drug resistance coloniesand cells derived therefrom are designated as hMYO-hERG.

HEK293 cells expressing hERG were prepared also by transduction. Morespecifically, HEK-hERG cells were prepared by transducing HEK293 cells(human embryonic kidney derived cells) with the pseudovirus particlesgenerated in Example 1 containing an expression vector that expresses aC-terminal FLAG-tagged hERG channel). This expression vector alsocontains a bicistronic eGFP reporter gene and confers puromycinresistance for positive selection and maintenance.

HeLa cells expressing hERG were also prepared by transduction. Morespecifically, HeLa cells were prepared by transducing HeLa cells withthe pseudovirus particles generated in Example 1 containing anexpression vector that expresses a C-terminal FLAG-tagged hERG channel).This expression vector also contains a bicistronic eGFP reporter geneand confers puromycin resistance for positive selection and maintenance.

The expression of hERG in the generated hMYO-hERG and HEK-hERG wereanalyzed and compared with control and other cell lines. The results areshown in FIGS. 4B-4C. As shown, the level of the hERG expression in thehMYO-hERG cells is substantially higher than control cells and otherhERG expressing cells (e.g., HEK-hERG and Hela-hERG cells). ThehMYO-hERG cells are designated as hERG-overexpressing cardiomyocytes.

6.3 Example 3: Cell Culture for Patch Clamp

Cell Culture, Cell Harvesting Reagents, and Electrophysiology Buffersfor Automated Patch Clamp Ionflux 16

Cell culture medium contains 89% DMEM/F12 (Life Technologies,11330-057), 10% FBS (Life Technologies, 26140-079), 1%Penicillin/Streptomycin (Life Technologies, 15140-122), and 10 μg/mLpuromycin (Life Technologies, A11138-03). 10 μg/ml puromycin is addedfreshly to the media after overnight incubation of the newlysub-cultured cells.

Serum free medium contains 100% DMEM/F12 (Life Technologies, 11330-057).

Harvesting agent contains 0.05% Trypsin-EDTA solution (LifeTechnologies, 25300-054).

Extracellular Ringer's Solution (ECS or EC buffer) contains Dulbecco'sphosphate-buffered saline (DPBS) (with calcium and magnesium) (Corning,21-030-CV), and 10 mM HEPES. The solution is adjusted to pH 7.4 withNaOH, and osmolarity is adjusted to be 300 mOsm with sucrose.

Intracellular Solution (ICS) contains 90 mM KF, 30 mM KCl, 11 mM EGTA,10 mM HEPES, and 2 mM MgCl₂. The solution is adjusted to pH 7.2 withKOH, and osmolarity is adjusted to be about 285 mOsm with KCl.

Culturing of Cells from Frozen Vials

One cryopreserved vial of cells (1×10⁶ cells/ml) was quickly thawed in37° C. water bath for 2 to 3 minutes. The cells were added to 7 mlpre-warmed growth cell culture medium, and pelleted by centrifugation at300×g for 5 minutes at room temperature. Aseptically aspirate thesupernatant without disturbing the cell pellet and gently re-suspend thecells in 15 ml of complete growth medium and then transfer to a new T75flask to culture at high density to optimize recovery. The cells weregrown in a 37° C. incubator with 5% CO₂ and 95% humidity, andsub-cultured after two days.

Sub-Culturing

The cells in a T75 flask were washed twice with PBS, and then treatedwith 2 ml 0.05% trypsin at 37° C. for 3 minutes to be detached from theflask. Trypsin was neutralized by adding 5 ml complete cell culturemedium, and the cells were gently re-suspended by pipetting up and down5 times. 2 ml of the resuspension was transferred into a new T75 flaskcontaining 13 ml cell culture medium. The cells were grown in a 37° C.incubator with 5% CO₂ and 95% humidity. Following overnight incubation,10 μg/ml puromycin was added to the flask to maintain the selection. Thecells were sub-cultured again when 70-80% confluency was reached (after2 to 3 days).

Cell Preparation for Automated Patch Clamp Experiments

When the cells reached 80% confluency in a T175 flask, they were shiftedfrom 37° C. to 28° C. (maintaining 5% CO₂ and 90% humidity) andincubated for 48 hours. Following this incubation, the cells were washedtwice with PBS and treated with 3 ml 0.05% trypsin at 37° C. for 3minutes. Most cells were floating with minimal amount of clumps undermicroscope. Trypsin was neutralized by adding 7 ml fresh cell culturemedia, and the cells were re-suspended by pipetting up and down 5-7times. The cells were pelleted at 300×g for 5 minutes at roomtemperature, then re-suspended in 6 ml serum free media, and incubatedat 37° C. for 30 minutes. Following the incubation, the cells werepelleted at 300×g, washed once with ECS, and re-suspended in ECS to afinal concentration of 3-5×10⁶ cells/ml. Following resuspension, anamount (250 μl) of the cell mixture was added to a designated well of anIonFlux 16 plate to perform the experiment.

6.4 Example 4: Comparison of hMYO Cells and hMYO-HERG Cells

In this exemplary study, hMYO-hERG cells stably expressing hERGdescribed herein were compared with hMYO cells.

Cells were prepared as described below. The cells were grown to 70% to90% confluency in a flask (at 37° C. and 5% CO₂) and removed from theincubator 1 to 3 days after plating. The cells were then incubated at30° C. and 5% CO₂ for 24-48 hours. After that, growth medium wasaspirated from the culture flasks and the cells were gently rinsed withwater or PBS to remove residual medium and dead cells. The cells werethen rinsed with a total of 3-5 ml of 0.05% trypsin-EDTA solution andthe flasks containing cells were incubated at 37° C. for 3-4 minutes. Atotal of 10 ml of complete media was added to the flask, and the cellswere gently dislodged from the flask. The mixture was centrifuged at300×g for 5 min at room temperature. The cell supernatant was decanted,and the cell pellet was resuspended in 5 ml of serum free medium orserum free CHO-SFM II medium, and incubated for 20-30 minutes at 28° C.and 5% CO₂. The cell suspension was then centrifuged at 300×g for 4 minand resuspended in ECS, followed by triturations using a 1000 μlpipettor. The cells were then pelleted with centrifugation and thebuffer was carefully aspirated. Cells were resuspended in fresh ECSbuffer and incubated for 5-10 minutes at room temperature, but for nomore than 20 minutes. 250 μl of the cell suspension was then added tothe ‘IN’ well of Ionflux16 plate (see FIG. 7A) just prior to theexperimental run. The cell suspension had a final concentration of about3 to 5 million cells per milliliter, and this corresponds to about750,000 to 1,250,000 cells per well.

As shown in FIG. 5A, the Ionflux 16 plate used in this study contains 8experimental regions (P1 to P8), and each region contains 12 wells (seeFIG. 5B). 2 wells are for trapping the cells (‘T1’ and ‘T2’); 8 wellsare for compounds (C1-C8); and 2 wells are for cell inlet “In” andoutlet “Out.” Cells are loaded in the inlet well, ICS is loaded into thetrapping wells, and 8 compounds (and/or solutions) are loaded into theremaining 8 wells. The wells are inter-connected through microfluidicchannels running within the well plate. Cells are pushed through themain flow channel and pulled onto an ensemble of 20 small pipette-likechannels by vacuum. There are two such ensembles in each experimentalpattern (or region)—T1 and T2, which are exposed to the same group of 8compounds (and/or solutions). A discrete patch clamp amplifier is usedfor continuous recording for each ensemble, and a patch clamp amplifierrecords a sum of currents across all 20 trapped cells resulting inconsistent data.

Immediately before the experiments, the cells were washed once in ECbuffer. The cells were then resuspended in EC buffer with aconcentration of 3-5×10⁶ cells/ml. Plates were primed for 3 minaccording to the following protocol: (1) traps and compounds at 8 psifor t=0-160 s and 1.6 psi for t=160-175 s, (2) traps but not compoundsat 1.6 psi for t=175-180 s, and (3) main channel at 1 psi for t=0-160 sand 0.2 psi for 160-180 s.

After cell introduction in to the proper inlet wells, the plates werere-primed as follows: (1) traps and compounds at 5 psi for t=0-15 s and2 psi for t=15-55 s, (2) traps but not compounds at 2 psi for t=55-60 s,and (3) main channel at 1 psi for t=0-20 s, 0.5 psi for t=20-40 s, and0.2 psi for t=40-60 s.

Then, cells were introduced into the main channel and trapped at lateraltrapping sites with a trapping protocol: (1) trapping vacuum of 6 mm Hgfor t=0-30 s and 4 mm Hg for t=30-85 s, (2) main channel pressure of 0.1psi for t=0-2 s, followed by 15 repeated square pulses of 0-0.2 psi withbaseline duration of 4.5 s and pulse duration of 0.5 s, followed by 0.1psi for 8 s.

One to five break protocols were performed and currents were stabilizedbefore compound testing. A negative control (EC buffer with 0.01% DMSO)was tested before compound testing.

Voltage command protocol(s) used in the study for hERG current wassimilar to those employed in conventional patch clamping: Vh was −80 mVand an initial step to +50 mV for 800 ms inactivated the channels,followed by a 1 s step to −50 mV to elicit the outward tail current thatwas measured (see FIG. 6 ).

The current of hMYO-hERG cells of passage No. 14 was compared with thecurrent of hMYO (control without hERG) at 37° C. in the Ionflux 16 platedescribed above. The hMYO cells were loaded on regions P1 and P2, andthe hMYO-hERG cells were loaded on regions P3 and P4. For each region,T1 and T2 cell trap zones were filled with ICS, and a singleconcentration of ECS buffer was applied five to eight times (C1-C8) tostudy the stability of whole-cell recordings. The different currentamplitude plateaus correspond to the ECS buffer applied at differenttimes. The voltage patch clamp protocol shown in FIG. 6 was performedand the current was measured.

The current obtained was leak-subtracted and represented in FIGS. 7A-7C.The current amplitudes at times C1-C5 for both cell lines are summarizedin Table 1 below, and rundown effect is analyzed by normalizing thecurrent amplitudes at times C2-C5 to that at C1.

TABLE 1 Current amplitudes at times C1-C5 for hMYO-hERG cells of passageNo. 14 PO3_T1 Norm to PO3_T2 Norm to PO4_T1 Norm to PO4_T2 Norm to CompdTime(s) (pA) C1 (%) (pA) C1 (%) (pA) C1 (%) (pA) C1 (%) C1 0 4263 1006005 100 3032 100 4550 100 C2 120 4533 106 6315 105 3544 117 4384 96 C3300 3779 89 5656 94 3650 120 4190 92 C4 480 4244 100 5652 94 3662 1213720 82 C5 660 4025 94 5490 91 3468 147 3557 78

As shown in FIGS. 7A-7C, the hMYO cells exhibited currents near zero(about −500 to −200 pA, see FIG. 7B); while the hMYO-hERG cellsexpressing hERG exhibited substantial stable current sweeps of about3500-6000 pA (see FIG. 7C). The magnitude of the current achieved in thehMYO-hERG cells is above 6000 pA and on an average of about 4000 pA, andthe current remains stable over a longer time period.

Table 1 also shows the stability of the current of the present hMYO-hERGcells with no or minor rundown effect (fainting of current over time).Table 1 shows the current amplitudes for each trap over time (C1-C5).Three trap zones (P3T2, P4T1, and P4T2) show no rundown effect over thetime course, and there is about 22% decrease in the magnitude of thecurrent in one of the trap zones (P3T1) (about 15-20% is generallyacceptable).

Rundown effect makes it difficult to calculate the true percentage ofinhibition by a compound since the decrease in current can be due toboth the compound treatment and the rundown effect. Thus, the hMYO-hERGcells stably expressing hERG as provided herein have an advantage overother currently available cell lines since the hMYO-hERG cells do notrequire the presence of ATP to give consistent high signals withoutrundown effect.

The experiments were repeated using hMYO-hERG cells of passage No. 17and passage No. 25. The results for the hMYO-hERG cells of passage No.17 are shown in FIG. 8 and Table 2. The results for the hMYO-hERG cellsof passage No. 25 are shown in FIG. 9 and Table 3.

TABLE 2 Current amplitudes at times C1-C5 for hMYO-hERG cells of passageNo. 17 PO5_T1 Norm to PO5_T2 Norm to Compd Time(s) (pA) C1 (%) (pA) C1(%) C1 0 3435 100 4342 100 C2 120 3383 98 4820 111 C3 300 3990 116 5154119 C4 480 3693 108 5132 118 C5 660 2790 81 4816 111

TABLE 3 Current amplitudes at times C1-C5 for hMYO-hERG cells of passageNo. 25 PO4_T1 Norm to PO4_T2 Norm to Compd Time(s) (pA) C1 (%) (pA) C1(%) C1 0 −73 100 2983 100 C2 120 −133 182 2954 99 C3 285 −70 96 2963 99C4 450 −283 388 3068 103 C5 615 −170 233 2563 86 C6 780 197 −270 2606 87C7 945 13 −18 2425 81 C8 1110 −107 147 2474 83

As shown, the magnitude of the current achieved for hMYO-hERG cells ofpassage No. 17 was between about 3500 to about 5000 pA, and remainedstable over the course of the experiment with no or minor rundown effect(see FIG. 8 and Table 2).

When hMYO-hERG cells of passage No. 25 were tested the cells were notpatched and one of the trap zones (P4-T1) did not work, but the trapzone P4-T2 worked well. After leak subtraction, a stable current sweepof about 2500 pA with a total rundown effect of about 17% (from C1 toC8) was obtained (see FIG. 9 and Table 3).

These exemplary results indicate that a stable current with no or minorrundown effect can be obtained using the hMYO-hERG cells even when thecells have gone through multiple passages.

6.5 Example 5: Evaluation of Herg Inhibitory Activities of Compoundswith Fully Automated High Throughput System

An evaluation of the hERG inhibitory activities with a compound withfull automated high throughput patch clamp system was performed usingthe hMYO-hERG cells provide herein.

FIG. 10 shows the block of hERG tail current by compound “E-4031” in thehMYO-hERG cells. E-4031(N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide)is a class Ill antiarrhythmic drug (see, e.g., Zhou et al. (1998)Biophys. J. 74: 230-41; Kim et al. (2005) J. Appl. Physiol. 98(4):1469-1477).

FIG. 11 shows the block of hERG tail current by quinidine in thehMYO-hERG cells. Quinidine is known to have strong hERG inhibitoryactivity (e.g., strong hERG blocker; see, e.g., Vincente et al. (2015) JAm Heart Assoc. 4(4): 1-13).

hERG currents were evoked by using standard voltage command used inconventional patch clamping as described above (see Example 4; see alsoFIG. 6 ) with some modifications. Currents were recorded at differentconcentrations of E-4031 (FIG. 10 ) and quinidine (FIG. 11 ). As may beseen from the figures, for normalized hERG current sweeps at 37° C.temperature, hERG expression is robust, exhibiting a mean tail currentamplitude of ˜3700 pA for E-4031 and ˜2700 pA for quinidine.

6.6 Example 6: Evaluation of hERG Inhibitory Activities of AdditionalCompounds with Fully Automated High Throughput System

An evaluation of hERG inhibitory activities of additional compounds withfull automated high throughout patch clamp system is performed using thehMYO-hERG cells as provided herein.

hERG currents are measured in the same manner as described in Examples 4and 5. With respect to the inhibitory activities of compounds againsthERG channels, inhibition ratios are calculated from the ratios of thepeak value of the tail current after the addition of variousconcentrations of the compound, taking the peak value of the tailcurrent recorded before the addition of the relevant compound as 100%.From the inhibition ratios of compounds at individual concentrations,hERG current inhibitory activity values (IC₅₀) are calculated.

Each compound is evaluated at the following concentrations, for example,at 0.01-30 μM. The drugs are allowed to act for about 3-15 minutes.

In the study, certain compounds that are already known to block hERGchannels or not block hERG channels when studied by standard patch clampcan be used as positive or negative controls.

In one exemplary study, each compound is used in eight patch platewells, generally allowing between three and eight successful cells (datapoints) at the one concentration. During the screen, each compoundconcentration is screened twice or more to ensure a sufficient number ofcells per data point.

6.7 Example 7: Evaluation of Cell Viability

An evaluation of the activity of compound to reduce cell viability wasperformed using the hMYO-hERG cell line as provided herein. Certaincompounds that are already known to inhibit or not inhibit hERG activitywere analyzed.

Ninety-six (96) well plate(s) were seeded with hMYO-hERG cellscontaining approximately 1×10⁴ cells/well. The plates were firstincubated for 24 hours at 37° C., 5% CO₂, followed by incubation for 48hours at 28° C., 5% CO₂. The wells were then treated with compound(s) ofinterest for 48 hours at standard cell cultural conditions. A negativecontrol medium without cells was included to determine backgroundsignal.

The cells were then assayed for toxicity using a SetuBlue™ CellProliferation Assay Kit (Fluorometric) (BioIntersect, Catalog#F6009-2500-A). This kit uses a Blue indicator dye, Resazurin, tomeasure the metabolic capacity of cells. Resazurin is a non-fluorescent,cell permeable and non-toxic compound. Viable cells efficiently reducethe Blue indicator dye to resorufin, which is highly fluorescent and anindicator of cell viability. Nonviable or dead cells rapidly losemetabolic capacity and are unable to reduce the indicator dye, and thusdo not generate a fluorescent signal.

The SetuBlue cell proliferation assay was performed as follows. The oldmedia was aspirated and replaced with fresh 100 μl medium containing 10%volume of SetuBlue reagent containing the Blue indicator dye. The plateswere incubated using standard cultural conditions for 1-4 hrs. Theplates were than shaken for 10-20 seconds before recording fluorescenceat 530/590 nm in PerkinElmer EnSpire® multimode plate reader. Therelative fluorescence unit (“RFU”) value of each control well wassubtracted from all RFU value to yield corrected RFU values. Thecorrected RFU values at 530/590 nm (Y axis, Log₁₀ scale) were plottedagainst concentration of test compound (X axis). The CC₅₀ value weredetermined by locating the X-axis value corresponding to one-half themaximum (plateau) RFU value using GraphPad Prism software.

FIG. 12A shows the results from one representative experiment, wherecorrected RFU Values at 530/590 nm (Y axis, Log₁₀ scale)±SEM is plottedagainst drug concentration (in μM). As shown in this figure,doxorubicin, which exhibits long-term cardiotoxicity but only slighteffects on hERG (see, e.g., Ducroq et al. (2010) British Journal ofPharmacology 159: 93-101; Moulin et al. (2015) Circ Heart Fail. 8(1):98-108; Guo et al. (2015) Curr Protoc Chem Biol. 7(3): 141-85; Mailletet al. (2016) Sci Rep. 4(6): 25333)) is cardiotoxic on the hMYO-hERGcell line at concentrations above 50 μM. The CC₅₀ value for doxorubicinwas determined to be 42.32 μM (see FIG. 12B). In contrast, quinidine,known to be a strong hERG blocker (see, e.g., Vincente et al. (2015) JAm Heart Assoc. 4(4): 1-13), is shown to be not significantlycardiotoxic on the hMYO-hERG cells at concentrations as high as 400 μM(compare to the control vehicle at 400 μM).

These results indicate that the hMYO-hERG cell line as provided hereincan be used to evaluate cardiotoxicity, independent of hERG blockage.

6.8 Example 8: Stable Cell Line Preparation

Cardiomyocytes expressing hERG were prepared by transducing cells asdescribed in Example 2 from AC10 adult human ventricular cardiomyocytes(ATCC Cat. No. PTA-1501), referred to herein as hMYO cells, with thepseudovirus particles generated in Example 1 containing an expressionvector that expresses a C-terminal FLAG-tagged hERG. This expressionvector also contains a bicistronic eGFP reporter gene and conferspuromycin resistance for positive selection and maintenance,

The cultured hMYO cells, were transduced at passage P3 and recombinantcardiomyocytes overexpressing hERG were generated. The recombinantcardiomyocytes stably expressing hERG were cultured through multiplepassages to generate a stable cell line, which was deposited with theATCC at passage P11. The deposited recombinant cardiomyocyte cell linewas designated as ATCC Designation No. PTA-123324. After deposit, thepassage P11 recombinant cardiomyocytes were designated P1 and furthercultured in multiple passages for further cell line stabilityassessment. In subsequent passages, between passages P4 to P10, therecombinant cardiomyocytes were sorted several times for high GFPexpression and kept under high puromycin (up to 50 μg/ml) selectionmedia. In subsequent passages, after P10, the recombinant cardiomyocyteswere tested up to passage P25 under drug selection (10 μg/ml). Thesepassaged recombinant cardiomyocytes produced high stable hERG currentswith an automated patch clamp machine. The deposited cells andsubsequent passaged cells were stable in their hERG expression and thestable cells lines were useful in screening methods as disclosed herein.

While this specification contains many specifics, these should not beconstrued as limitations on the scope or of what may be claimed, butrather as descriptions of features specific to particular embodiments.Certain features that are described in this specification in the contextor separate embodiments can also be implemented in combination in asingle embodiment. Conversely, various features that are described inthe context of a single embodiment can also be implemented in multipleembodiments separately or in any suitable subcombination. Moreover,although features may be described above as acting in certaincombinations and even initially claimed as such, one or more featuresfrom a claimed combination can in some cases be excised from thecombination, and the claimed combination may be directed to asubcombination or variation of a subcombination.

Thus, particular embodiments have been described. Other embodiments arewithin the scope of the following claims. For example, the actionsrecited in the claims can be performed in a different order and stillachieve desirable results.

All publications and patent applications cited in this specification areherein incorporated by reference as if each individual publication orpatent application were specifically and individually indicated to beincorporated by reference. Although the foregoing has been described insome detail by way of illustration and example for purposes of clarityof understanding, it will be readily apparent to those of ordinary skillin the art in light of the teachings of the specification that certainchanges and modifications may be made thereto without departing from thespirit or scope of the appended claims.

1. A recombinant cell line comprising recombinant cardiomyocytes stablyexpressing hERG.
 2. The recombinant cell line of claim 1, wherein therecombinant cardiomyocytes comprise a transduced nucleic acid sequenceencoding hERG.
 3. The recombinant cell line of claim 1, wherein hERGcomprises an amino acid sequence as set forth in amino acids 1-1159 ofSEQ ID NO:
 1. 4. The recombinant cell line of claim 1, wherein the cellline is designated hMYO-hERG (ATCC Designation No. PTA-123324).
 5. Therecombinant cell line of claim 1, wherein the recombinant cardiomyocytesare progeny, descendants or derivatives of hMYO-hERG (ATCC DesignationNo. PTA-123324).
 6. A stable cardiomyocyte cell line overexpressing hERGcomprising recombinant cardiomyocytes that are progeny, descendants orderivatives of hMYO-hERG (ATCC Designation No. PTA-123324).
 7. A methodof preparing the cell line according to claim 1, comprising:transfecting or transducing human cardiomyocytes with a nucleic acidsequence encoding hERG; and selecting the cardiomyocytes stablyexpressing hERG.
 8. The method of claim 7, wherein the transfecting ortransducing is with a vector comprising the nucleic acid sequence. 9.The method of claim 8, wherein the vector is a retroviral vector. 10.The method of claim 9, wherein the vector is a lentiviral vector. 11.The method of claim 10, further comprising generating pseudo-lentiviralparticles.
 12. A method for determining cardiotoxicity of a compoundusing the cell line of claim
 1. 13. A method of screening compounds forhERG inhibitory activity comprising using the cell line of claim
 1. 14.A method for determining the activity of a compound to inhibit hERGcomprising using the cell line of claim
 1. 15. A method for determiningthe activity of a compound to inhibit hERG comprising: a) providingrecombinant cardiomyocytes overexpressing hERG; b) contacting thecardiomyocytes with the compound; c) measuring a test current; and d)determining if the test current is reduced in the presence of thecompound, wherein a reduced test current is indicative of hERGinhibitory activity.
 16. The method of claim 15, wherein the testcurrent is measured with electrophysiology techniques.
 17. The method ofclaim 15, wherein the test current is measured with a patch clampapparatus.
 18. The method of claim 15, wherein the test current iscompared before and after contacting the recombinant cardiomyocytes withthe compound.
 19. The method of claim 15 wherein the recombinantcardiomyocytes are derived from the cell line designated hMYO-hERG (ATCCDesignation No. PTA-123324).
 20. The method of claim 15, wherein therecombinant cardiomyocytes are progeny, descendants or derivatives ofhMYO-hERG (ATCC Designation No. PTA-123324).
 21. A method fordetermining the ability of a compound to reduce cell viabilitycomprising using the cell line of claim
 1. 22. A method for determiningthe activity of a compound to reduce cell viability comprising: a)providing recombinant cardiomyocytes overexpressing hERG; b) contactingthe cardiomyocytes with the compound in the presence of a viabilityindicator compound; c) measuring a signal of the indicator compound; andd) determining if the signal is reduced or increased in the presence ofthe compound, wherein a reduced or increased signal is indicative ofreduced cell viability.
 23. The method of claim 22, wherein theindicator compound is an indicator dye.
 24. The method of claim 22,wherein the signal of the indicator compound is an absorbance,luminescence or fluorescence signal.
 25. The method of claim 22, whereinthe signal is compared before and after contacting the cardiomyocyteswith the compound.
 26. The method of claim 22 wherein the recombinantcardiomyocytes are from the cell line designated hMYO-hERG (ATCCDesignation No. PTA-123324).
 27. The method of claim 22, wherein therecombinant cardiomyocytes are progeny, descendants or derivatives ofhMYO-hERG (ATCC Designation No. PTA-123324).
 28. A kit comprising therecombinant cardiomyocytes from the cell line of claim 1.